

# 14<sup>th</sup>

## Congress of the World Federation of Nuclear Medicine and Biology

# WFNMB

Cartagena de Indias  
Colombia

# 2026

13-16 February



# Scientific Programme

Organized by



WORLD FEDERATION  
OF NUCLEAR MEDICINE  
AND BIOLOGY



ACMNIM  
ASOCIACIÓN COLOMBIANA  
DE MEDICINA NUCLEAR  
E IMÁGENES MOLECULARES



alasbimn  
Asociación Latinoamericana de Sociedades  
de Biología y Medicina Nuclear

In cooperation with



IAEA

# Index

---

- 03 Welcome Letter
- 04 Road to Cartagena
- 05 Committees
- 09 About the Congress
- 13 Scientific Information
- 17 EACCME Accreditation Information
- 19 Scientific Programme Outline
- 23 Scientific Programme
- 63 List of Oral Presentations
- 79 List of E-Posters



# Welcome Letter

**Dear Friends and Colleagues,**

The **14th World Congress of the World Federation of Nuclear Medicine and Biology (WFNMB)** is approaching.

It will take place from February 13th to 16th, 2026, in Colombia, in the beautiful city of Cartagena.

On behalf of the World Federation of Nuclear Medicine and Molecular Biology (WFNMB) and the Colombian Association of Nuclear Medicine and Molecular Imaging (ACMNIM), I would like to invite you to join us and actively participate, as it will be the ideal setting for discussion of topics focused on personalized patient management: diagnosis, treatment, follow-up, accompaniment, etc.

Coming to Cartagena will be an opportunity to strengthen our friendships, as we firmly believe that interaction and collaboration among nuclear medicine professionals are the keys to enhancing our specialty.

Sincerely,



**Patricia Bernal Trujillo**

President of the 14th World Congress  
of Nuclear Medicine of the WFNMB  
Cartagena 2026

# Road to Cartagena

## Algiers

24 January, 2025  
Virtual webinar

## Nuclear Medicine Update

6–9 February, 2025  
Singapore

## Latin American Congress of Nuclear Medicine (ALASBIMN)

13–17 March, 2025  
Cancún

## Balkan Congress of Nuclear Medicine

8–11 May, 2025  
Athens

## Annual Scientific Meeting of the Australian & New Zealand Society of Nuclear Medicine

23–25 May, 2025  
Melbourne

## Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting

21–24 June, 2025  
New Orleans

## International Conference on Radiopharmaceutical Therapy (ICRT)

6–9 November, 2025  
Cyprus

## Congress of the World Federation of Nuclear Medicine & Biology (WFNMB)

13–16 February, 2026  
Cartagena de Indias

## Organizing Committee

---



**Patricia Bernal Trujillo**  
*President*



**Carlos Granados**  
*Scientific committee*



**Amelia de los Reyes**  
*Budget committee*



**Emperatriz Angarita**  
*Logistics committee*



**Aiken Betancourt**  
*Local committee*



**Juan Luis Londoño**  
*Auditor*



**Víctor Marín**  
*Abstracts Committee*

## International Committee

---



**Dr. Mariela  
Agolti**  
*Argentina*



**Dr. Akram  
Al-Ibraheem**  
*Jordan*



**Dr. María  
Bastianello**  
*Argentina*



**Dr. Richard  
Baum**  
*Germany*



**Dr. Salah  
Bouyucef**  
*Algeria*



**Tec. Tina  
Buehner**  
*USA*



**Dr. Juliano  
Cerci**  
*Brazil*



**Dr. Arturo  
Chiti**  
*Italy*



**Dr. Partha  
Choudhury**  
*India*



**Dr. Marcelo  
DiCarli**  
*USA*



**Dr. Gisela  
Estrada**  
*Mexico*



**Dr. Stefano  
Fanti**  
*Italy*

## International Committee

---



**Dr. Savvas  
Frangos**  
*Cyprus*



**Dr. Camilo  
García**  
*France*



**Dr. Gopinath  
Gnanasegaran**  
*United Kingdom*



**Dr. Gabriel  
Grossman**  
*Brazil*



**Dr. Michael  
Hoffman**  
*Australia*



**Dr. Ioannis  
Koutsikos**  
*Greece*



**Dr. Rakesh  
Kumar**  
*India*



**Dr. Lizette  
Louw**  
*South Africa*



**Dr. Raluca  
Mititelu**  
*Romania*



**Dr. Erick  
Mora**  
*Costa Rica*



**Dr. Fernando  
Mut**  
*Uruguay*



**Tec. Margarita  
Núñez**  
*Uruguay*

## International Committee

---



**Dr. Edel  
Noriega**  
*Spain*



**Dr. Diana  
Páez**  
*Colombia*



**Lic. Mariano  
Portillo**  
*Argentina*



**Dr. Mike  
Sathekge**  
*South Africa*



**Dr. Andrew  
Scott**  
*Australia*



**Dr. Gonzalo  
Ucros**  
*Colombia*



**Dr. Jean-Luc  
Urbain**  
*USA*



**Dr. Irene  
Virgolini**  
*Austria*

# About the Congress



## Venue

### Cartagena de Indias Convention Center

*Cl. 24 #8A-344, Getsemaní, Cartagena de Indias, Bolívar, Colombia*

The **Cartagena de Indias Convention Center** emerged as the Ministry of Commerce, Industry and Tourism's project in 1978, thought out to work as a regional development generator, facilitating wide attendance activities such as conferences, events and conventions. The venue was designed by the Esguerra, Sáenz y Samper Ltda. firm and built by the local Civilco firm. Our carefully designed infrastructure and strategic location, right in the middle of Cartagena de Indias's World Historical Heritage downtown area, provide a strong competitive edge which has allowed us to host every major event that has taken place in Colombia since our opening in 1982.



## Registration and Hours of the Technical Secretariat



**The printing of badges for the Congress days will take place at the 'Registration Portico.'**

This access to the Convention Center is located in front of the 'Values of Cartagena' statue on Calle 24.

# About the Congress

This registration area will be open during the following hours:

<b>Thursday, February 12</b>	16.00h – 19.00h
<b>Friday, February 13</b>	07.00h – 19.00h
<b>Saturday, February 14</b>	07.30h – 18.00h
<b>Sunday, February 15</b>	07.30h – 18.00h
<b>Monday, February 16</b>	07.30h – 12.00h

## Important

**Carry your credential visible at all times, as it is essential for access to all areas of Congress.**

Be careful and keep an eye on your belongings at all times. In case of loss, participants can ask about lost items at the “Help Desk” counter located in the Registration Portico.



## Congress Language

As this is an International Congress, **all conferences and question-and-answer sessions will be conducted in English**, with the exception of the “Technologists Symposia” on Saturday and Sunday. For these sessions, presentation slides must be in English; however, the presentations may be delivered in Spanish.



## Congress Dress Code

**Business Formal** or **Business Casual** accepted.



## Wi-Fi

Free basic Wi-Fi service available in all areas:

**Network:** Ciclotron Colombia

**Password:** CiclotronColombia2026



## WFNMB 2026 App

**Download the Congress App** to consult the scientific program and stay up to date with all congress activities.

# About the Congress

Please note that **there will be no printed version of the Congress Program**. We strongly encourage you to download the official app, where you will find the most up-to-date program, activities, notifications, and relevant event information.

## Note:

By default, the Congress App displays the program according to the device's local time zone. If the app is accessed from a country other than Colombia, session times may appear adjusted. Please remember to select the event time zone in the **"Privacy and Settings"** section of the app.

[Download the WFNMB 2026 App](#)



## Q&A

At the end of each session there will be time for questions and answers. Questions may be asked using the microphone in the room or through the Congress App. The Chairs of each session will receive the questions, select them, and pose them to the speakers. You can access the question module by selecting the session in the scientific program within the App.



## Speakers Room (Room 101)

Speakers are **required to bring their presentation on a USB flash drive and upload it in the Speakers' Room (Room 101)** in advance of their session.

We kindly ask that you upload your presentation(s) **at least two hours before your scheduled session**. If your session is scheduled for early in the morning, we recommend uploading your file the day before.

**The room will be available during Congress hours from February 13 to 16.** On **February 12**, presentations can also be submitted starting at **3:00 PM**.

[Presentation Template](#)

# About the Congress



## Certificates

Certificates of attendance and presentations (oral and e-posters) will be sent **by email after the conclusion of the congress.**



## Coffee Break

**They will take place at the Claustro de las Ánimas** from Friday through Monday, in both the Morning and Afternoon, at the following times:

### Friday, February 13

16:00h – 16:30h

### Saturday, February 14

10:00h – 10:30h

16:00h – 16:30h

### Sunday, February 15

10:00h – 10:30h

16:00h – 16:30h

### Monday, February 16

10:00h – 10:30h



## Lunch Break

Please note that **the Congress does not include lunch.** However, collaborating **companies will provide food and/or drinks during their commercial symposiums** that will take place during lunchtime, from 12:15h to 1:45 p.m., on February 14 and 15.



## Welcome Cocktail

**Date:** Friday, February 13th

**Venue:** Claustro de las Ánimas, Cartagena de Indias Convention Center

**Dress Code:** Smart casual

**Access:** Included in the registration fee



## Congress Dinner

**Date:** Sunday, February 15th

**Venue:** Gran Salón Barahona, Cartagena de Indias Convention Center.

**Dress Code:** Elegant smart casual – stylish and refined attire suitable for an evening of dinner and dancing.

**Access:** Included in the registration fee (*please ensure your participation is confirmed by January 15th*).



## Presentation Guidelines for Speakers

- Please download and use the [official template](#) when preparing your presentation.
- **Slide format must be 16:9.** Please adapt your presentation to this format to ensure correct display on the screen.
- All presentations must be in **Microsoft PowerPoint format** (version 2019 or higher).
- In this document, you will find full **details of your participation, including the session, date, time, room, and your assigned presentation slot.**
- **All presentations must be delivered exclusively in English.** For the Technologists Symposia on Saturday and Sunday, slides must be in English, but the oral presentation may be delivered in Spanish.
- All rooms will be equipped with standard audiovisual facilities, including a projector, sound system, microphones, and a computer for displaying presentations. **The use of personal laptops is not allowed.**



## Upload your Presentation in the Speakers' Room

- **Speakers are required to bring their presentation on a USB flash drive and upload it in the Speakers' Room (Room 101) in advance of their session.**
- We kindly ask that you upload your presentation(s) **at least two hours before your scheduled session.** If your session is scheduled for early in the morning, **we recommend uploading your file the day before.**
- **The room will be available during Congress hours from February 13 to 16.** On **February 12**, presentations can also be submitted **starting at 3:00 PM.**
- It is very important to **check with the technician to ensure that your presentation displays correctly**—including slides, videos, and audio— in order to avoid any issues during your session.
- If your presentation includes a video, **we recommend that you also provide the original video file separately** to the technician to help prevent playback issues during your talk.

## General Information for Session Chairs

- Please **adhere to the scheduled times** to ensure the session runs smoothly. If a speaker does not show up, feel free to manage the available time as you see fit.
- At the start of the session, **welcome the speakers and introduce yourself as the chair**. Additionally, **be sure to announce each speaker's name** and the **title of their presentation**, then invite them to the podium.
- **Each chair will be provided with a tablet** containing the **scientific program**, **speakers' bios** and **photos**, as well as **questions submitted** via the WFNMB 2026 App.
- **Audience questions will be submitted through the Congress App**. At the start of the session, please kindly **remind the audience** that they are **welcome to submit questions** in English at any time via the app. Please also remind the speakers that the final minutes of their presentations are reserved for questions.
- Review the questions received on your tablet and **select the most interesting or relevant ones** to pose to the speakers. It is recommended that one of the chairs continuously reviews incoming questions throughout the presentations so that pre-selected questions are ready when the Q&A time begins.
- **Handheld microphones will also be available** in the rooms for questions **but we recommend using the app** to manage questions more smoothly during the session.
- **No printed version of the program** will be provided. **All session content will be accessible in** the WFNMB 2026 App and the [official Congress website](#), which you can review in advance if you wish.

## General Information for Oral Presentations

- Please download and use the [official template](#) when preparing your presentation.
- The full schedule of oral communications is available on the Congress website: [WFNMB 2026 Scientific Program](#).

- At the beginning of this email, you will find complete **details of your participation, including session, date, time, room, and your assigned presentation slot.**
- The assigned **'Paper Reference'** code identifies the type and number of your presentation (001: Oral presentation 01).
- **Each oral presentation has a total duration of 7 minutes:** 5 minutes for the presentation and 2 minutes for questions and answers. We kindly ask you to adhere strictly to the allotted time to ensure the smooth progression of the session.
- **All presentations must be delivered exclusively in English.**
- All rooms will be equipped with standard audiovisual facilities, including a projector, sound system, microphones, and a computer for displaying presentations. **The use of personal laptops is not allowed.**



## Instructions for Submitting Presentations

- **Presenters must bring their presentation on a USB flash drive** and submit it to the Speaker Room (Room 101) with sufficient advance time. The room will be available during Congress hours from February 13 to 16. On February 12, presentations can also be submitted starting at 3:00 PM.
- All presentations must be submitted in **PDF format. No animations, videos, or transitions** are allowed.
- The number of slides should be appropriate for a **5-minute presentation.**



## General Information about E-Posters

- Your poster **must be submitted in digital format (E-Poster).**
- Please **read the instructions** below carefully before creating your E-Poster.
- To **upload your E-Poster**, please access the platform and follow the steps provided. The process is simple and intuitive: [E-Poster Submission Portal](#).
- The **deadline** for submitting your E-Poster is **Friday, January 9, 2026.**

- All E-Posters will be displayed on interactive screens in the “**Claustro de las Ánimas**” hallway, where the commercial exhibition takes place.
- There will be **no in-person poster presentations**. However, during the coffee breaks and lunch times, which will serve as poster walks, it will be a great opportunity to be near the screens and interact with other attendees interested in the E-Posters.



## Instructions for Preparing Your E-Poster

- Before you begin, please [download and use the official template](#), which contains the required dimensions and format.
- The E-Poster must consist of **one single vertical slide** (vertical format) and must be saved as a **PDF file**. Maximum: **1 slide**.
- Please **include your contact details and email address** so that interested attendees can easily reach you with any questions or further information they may need.
- You are free to design your E-Poster as you consider appropriate, but we recommend the following guidelines:
  1. Use fonts such as **Arial, Tahoma, or Verdana**.
  2. Choose a **white or light background** with high-contrast text colors.
  3. Insert all images **directly into the slide**; please avoid external links.
  4. **Animations and effects are not allowed**.

## Accreditation Statement

“The 14th World Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), Cartagena de Indias, Colombia 13/02/2026 - 16/02/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 19.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.”

“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”


## How to Apply for EACCME® Credits

Each participant can only receive the number of credits he/she is entitled to according to their **actual participation** at the event. Sessions accredited per day are indicated in the program with **“CME”** in the title.

Credit will be converted based on one (1) hour of participation equalling one credit for all activities.

To claim your EACCME® credits, **you must respond to a survey in the Congress App for each scientific session you attend**. Please follow these steps:

# EACCME Accreditation Information



1. **Download the Congress App.**
2. **Select the session** you are attending.
3. **Once the session has concluded**, you must respond to a survey by tapping **“Start Survey”** in the selected session within the App. The survey **closes 15 minutes after the session has finalized.**
4. **Answer the session survey** and click **“Submit”**. Our system will record the **date and time** of your attendance.

## EACCME® Certificate

The EACCME® Certificate will be sent **after the Congress**. To receive your certificate, you must complete the **Feedback Form**, which will be sent to you by email after the Congress.

# Scientific Programme Outline

- WFNMB Congress Sessions
- Radiopharmacy and Chemistry
- Medical Physics
- Nuclear Medicine Students Course
- Technologists
- WARMTH
- ISORBE
- Industry symposia and Workshops
- ALASBIMN Meetings
- Oral Presentations
- Workshops

## Friday, February 13

Getsemaní   Barahona 1   Barahona 2   Barahona 3   Barahona 4   Arsenal   Pegasos   Secretaría General

Pre-Congress Activities								
7:30 am - 9:00 am								● Asamblea Informativa de la Asociación Colombiana de Medicina Nuclear e Imágenes Moleculares
8:00 am - 9:40 am			● Nuclear Medicine Students Course (1)	● Pre-Congress Course: Radiopharmacy and Chemistry (1)	● Pre-Congress Course: Internal Dosimetry in Clinical Practice: From Fundamentals to Advanced Tools and Applications (1)	● WFNMB & SBMN Session: AI in Radiopharmacy, Oncology, and Cardiology		
9:10 am - 10:00 am								● First ALASBIMN Meeting of Young Professionals
9:40 am - 10:00 am	Morning Break							
10:00 am - 12:00 pm	● "Challenges and Nuclear Medicine Opportunities of Nuclear Medicine Around the World". Organised by World Federation of Nuclear Medicine and Biology and the International Atomic Energy Agency	● Nuclear Medicine Students Course (2)	● Pre-congress Course: Radiopharmacy and Chemistry (2)	● Pre-congress Course: Internal Dosimetry in Clinical Practice: From Fundamentals to Advanced Tools and Applications (2)				
10:30 am - 12:00 pm								● Meeting between ALASBIMN and Associations and Institutions

# Scientific Programme Outline

- WFNMB Congress Sessions
- Technologists
- ALASBIMN Meetings
- Radiopharmacy and Chemistry
- WARMTH
- Oral Presentations
- Medical Physics
- ISORBE
- Workshops
- Nuclear Medicine Students Course
- Industry symposia and Workshops

## Friday, February 13

Getsemaní   Barahona 1   Barahona 2   Barahona 3   Barahona 4   Arsenal   Pegasos   Secretaría General

World Congress Activities								
2:00 pm – 4:00 pm		● CME: Session: SPECT/CT in the PET/CT Era	● WARMTH Symposia (ISRT). Novel Therapies I	● Session: Nuclear Cardiology	● Session in Medical Physics: 25 Years of PET/CT: Past, Present, and the Hybrid Future	● Oral Presentations I: Neurology, Radiopharmacy and Chemistry	● Workshop "Radioguided Tasting Menu"	● ALASBIMN Board of Directors and Presidents of National Societies Meeting & Meeting on ALASBIMN Committees
4:00 pm – 4:30 pm	Afternoon Break							
4:30 pm – 4:50 pm	● Inauguration: President of Congress – President of WFNMB							
4:50 pm – 6:00 pm	● CME: Plenary Session: Strategic Integration of Nuclear Medicine into Global Health Policy: From The Lancet Oncology Commissions to the WHA78.13. Resolution on Strengthening Medical Imaging Capacity							
6:00 pm – 7:00 pm	● Welcome Reception							

# Scientific Programme Outline

- WFNMB Congress Sessions
- Radiopharmacy and Chemistry
- Medical Physics
- Nuclear Medicine Students Course
- Technologists
- WARMTH
- ISORBE
- Industry symposia and Workshops
- ALASBIMN Meetings
- Oral Presentations
- Workshops

## Saturday, February 14

	Getsemaní	Barahona 1	Barahona 2	Barahona 3	Barahona 4	Arsenal	Pegasos	Secretaría General
8:00 am – 10:00 am		● CME: Session: PET CT in Hematological Disease	● WARMTH Symposia (ISRT). Novel Therapies II	● ALASBIMN: Radiopharmacy (1)	● Technologists Symposia (1)	● Oral Presentations 2: Physics and Technology	● Workshop on Molecular Brain Imaging of Dementia: Read with Expert	● Industry Workshop (1)
10:00 am – 10:30 am	Morning Break							
10:30 am – 11:45 am	● CME: Plenary Session: Cardiology							
11:45 am – 12:15 m	Noon Break							
12:15 m – 1:45 pm		● Industry Symposium (1)	● Industry Symposium (2)	● Industry Symposium (3)	● Industry Symposium (4)	● Industry Symposium (5)	● Industry Symposium (6)	● Industry Symposium (7)
2:00 pm – 4:00 pm		● CME: Session: Molecular Imaging in Neurology	● Session: Nuclear Medicine-Guided Procedures	● ALASBIMN: Radiopharmacy (2)	● Technologists Symposia (2)	● Oral Presentations 3: Cardiology, Infection and Inflammation	● Medical Physics Workshop: Practical Dosimetry Using MIRDsoft	● WFNMB Assembly
4:00 pm – 4:30 pm	Afternoon Break							
4:30 pm – 5:45 pm	● CME: Plenary Session: Technological Advances in Nuclear Medicine (1)							
5:45 pm – 6:15 pm	● Plenary Session: Technological Advances in Nuclear Medicine (2)							

# Scientific Programme Outline

- WFNMB Congress Sessions
- Radiopharmacy and Chemistry
- Medical Physics
- Nuclear Medicine Students Course
- Technologists
- WARMTH
- ISORBE
- Industry symposia and Workshops
- ALASBIMN Meetings
- Oral Presentations
- Workshops

## Sunday, February 15

	Getsemaní	Barahona 1	Barahona 2	Barahona 3	Barahona 4	Arsenal	Pegasos	Secretaría General
8:00 am – 10:00 am	● CME: Session: Theranostics in Prostate Cancer	● Session: Lung Cancer	● Oral Presentations 4: Therapy and Radioguided Procedures	● ISORBE Symposia (1)	● Technologists Symposia (3): Quantitative Imaging: from Harmonization to Clinical Metrics	● Industry Symposium (8)	● Industry Symposium (9)	● Industry Workshop (2)
10:00 am – 10:30 am	Morning Break							
10:30 am – 11:45 am	● CME: Plenary Session: Thyroid Cancer							
11:45 am – 12:15 m	Noon Break							
12:15 pm – 2:15 pm						● Oral Presentations 5: Oncology 1 (NETs and Prostate)		
12:15 m – 1:45 pm		● Industry Symposium (10)	● Industry Symposium (11)	● Industry Symposium (12)	● Industry Symposium (13)			● Industry Symposium (15)
2:00 pm – 4:00 pm	● CME: Session: Molecular Imaging in Solid Tumors	● ASNC Nuclear Cardiology Workshop for Physicians: PET and SPECT Myocardial Flow Quantification	● ALASBIMN: Cyclotron Symposium	● Technologists Symposia (4)			● Industry Symposium (14)	● From WHA78.13 on Strengthening Medical Imaging Capacity to Action – Stakeholders Meeting
4:00 pm – 4:30 pm	Afternoon Break							
4:30 pm – 6:30 pm	● CME: Plenary Session: Prostate Cancer							

## Monday, February 16

	Barahona 1	Barahona 2	Barahona 3 + Barahona 4	Arsenal
8:00 am – 10:00 am	● Session: Theranostics and Humanistic Approaches	● Session: Pediatric Nuclear Medicine	● CME: Session: Theranostics in NETs	● Oral Presentations 6: Oncology 2 and Endocrinology
10:00 am – 10:30 am	Morning Break			
10:30 am – 11:10 am			● CME: Plenary Session: From Detection to Decision: How Next Generation Cancer Imaging will Drive Precision Oncology	
11:10 am – 1:00 pm			● Closing Session	

## Auditorio Getsemaní

- 16:30 – 16:50**    **Inauguration: President of Congress – President of WFNMB**  
Chair: Dr. Gopinath Gnanasegaran (United Kingdom)
- 16:30 – 16:40**    **Speech by the President of Congress**  
Dr. Patricia Bernal Trujillo  
*WFNMB (Colombia)*
- 16:40 – 16:50**    **Speech by the President of the WFNMB**  
Dr. Savvas Frangos  
*World Federation of Nuclear Medicine and Biology (Cyprus)*
- 16:50 – 18:00**    **CME: Plenary Session: Strategic Integration of Nuclear Medicine into Global Health Policy: From The Lancet Oncology Commissions to the WHA78.13. Resolution on Strengthening Medical Imaging Capacity**  
Chairs: Prof. Homer A. Macapinlac (United States) and Dr. Savvas Frangos (Cyprus)
- 16:50 – 17:00**    **WHO Resolution on Strengthening Medical Imaging**  
Prof. John Prior  
*Wfnmb and Lausanne University Hospital (Switzerland)*
- 17:00 – 17:10**    **Cost-Effectiveness of Nuclear Medicine**  
Prof. Andrew Scott  
*Department of Molecular Imaging and Therapy, Austin Health (Australia)*
- 17:10 – 17:20**    **Implementation Pathways through IAEA**  
Dr. Diana Páez  
*International Atomic Energy Agency (Austria)*
- 17:20 – 17:30**    **Epidemiology & Resource Reality**  
Lic. Mariano Portillo  
*Instituto Alexander Fleming (Argentina)*
- 17:30 – 17:50**    **Panel Discussion & Q \ &A**
- 17:50 – 18:00**    **Closing Remarks**  
Dr. Savvas Frangos and Dr. Homer Macapinlac

## Barahona Room 1

- 10:00 – 12:00** **Challenges and Opportunities of Nuclear Medicine Around the World. Organised by World Federation of Nuclear Medicine and Biology and the International Atomic Energy Agency**  
**Chairs:** Dr. Diana Páez (Austria) and Dr. Savvas Frangos (Cyprus)
- 10:00 – 10:05** **Introduction**  
 Dr. Savvas Frangos  
*World Federation of Nuclear Medicine and Biology (Cyprus)*
- 10:05 – 10:25** **The Example of Romania: From almost “Nothing” to “Everything”: The road to success**  
 Dr. Raluca Mititelu  
*University of Medicine and Pharmacy Carol Davila Bucharest; Central University Emergency Military Hospital Bucharest (Romania)*
- 10:45 – 11:05** **Brazil as example of the introduction of WHO resolution**  
 Prof. Elba Etchebehere  
*Brazilian Society of Nuclear Medicine and Molecular Imaging (Brazil)*
- 11:05 – 11:25** **Nuclear Medicine Theragnostics in Africa: Current status, Challenges and Future Prospects**  
 Dr. Masha Maharaj  
*Umhlanga Molecular Imaging and Therapy. Centre Of Excellence (South Africa)*
- 11:25 – 11:55** **Round Table discussion: All the participants**
- 11:55 – 12:00** **Conclusions**  
 Dr. Diana Páez  
*International Atomic Energy Agency (Austria)*
- 14:00 – 16:00** **CME: Session: SPECT/CT in the PET/CT Era**  
**Chairs:** Dr. Gonzalo Ucrós (Colombia) and Prof. Rajesh Kumar (India)
- 14:00 – 14:25** **State of the art and advances in SPECT/CT, Full-Ring CZT PET/CT systems**  
 Prof. Karin Knešaurek  
*Icahn School of Medicine At Mount Sinai (United States)*

- 14:25 – 14:50 Bone SPECT/CT**  
Prof. Rakesh Kumar  
*All India Institute of Medical Sciences (AIIMS)  
(India)*
- 14:50 – 15:15 Other clinical applications of SPECT-CT**  
Dr. Gabriel Soudry  
*Medstar Health (United States)*
- 15:15 – 15:40 Precision advantage: Quantitative SPECT/CT in guiding theranostics strategies**  
Dr. Munir Ghesani  
*United Theranostics (United States)*

## Barahona Room 2

- 08:00 – 09:40 Nuclear Medicine Students Course (1)**  
**Chairs:** Dr. Daniel Felipe Galindo-Cortés (Colombia)  
and Dr. Gopinath Gnanasegaran (United Kingdom)
- 08:10 – 08:30 Parathyroid Scintigraphy –Choline PET CT- a disruptor here to stay or a pretender?**  
Dr. Hosahalli K. Mohan  
*Barts Health Nhs Trust (United Kingdom)*
- 08:30 – 08:50 Radionuclide Bone scintigraphy (18F-NaF)**  
Dr. Muhammad Sharjeel Usmani  
*Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCRC), University Medical City, Muscat Oman (Oman)*
- 08:50 – 09:10 PET-MRI clinical applications**  
Dr. Muhammad Umar Khan  
*Al-Jahra Hospital (Kuwait)*
- 09:10 – 09:40 Signs in Nuclear Medicine**  
Dr. Gopinath Gnanasegaran  
*Royal Free London Nhs Foundation Trust (United Kingdom)*

**09:40 – 10:00 Morning Break**

- 10:00 – 12:00** **Nuclear Medicine Students Course (2)**  
**Chairs:** Dr. Daniel Felipe Galindo-Cortés (Colombia) and Dr. Gopinath Gnanasegaran (United Kingdom)
- 10:00 – 10:20** **Radionuclide renal imaging**  
 Dr. Karuppiah Kumaresan Nadar  
*KK Nuclear Scans (India)*
- 10:20 – 10:40** **Radionuclide thyroid imaging**  
 Dr. Karuppiah Kumaresan Nadar  
*KK Nuclear Scans (India)*
- 10:40 – 11:00** **<sup>68</sup>Ga-DOTATATE PET-CT in NETs**  
 Dr. Gopinath Gnanasegaran  
*Royal Free London Nhs Foundation Trust (United Kingdom)*
- 11:00 – 11:20** **FDG PET-CT in Lymphoma**  
 Dr. Nagabhushan Seshadri  
*Liverpool University Hospital (United Kingdom)*
- 11:20 – 11:40** **How to manage common pitfalls in PET-CT imaging**  
 Dr. Muhammad Umar Khan  
*Al-Jahra Hospital (Kuwait)*
- 14:00 – 16:00** **WARMTH Symposia (ISRT). Novel Therapies I**  
**Chairs:** Dr. Mariela Agolti (Argentina), Prof. Sze Ting Lee (Australia) and Dr. Masha Maharaj (South Africa)
- 14:05 – 14:15** **CCK2 receptor theragnostics**  
 Prof. Irene Virgolini  
*Department of Nuclear Medicine, Medical University of Innsbruck (Austria)*
- 14:15 – 14:30** **Evaluating Terbium-161 outcomes from Single-Arm, Tandem, and Triple Tandem Radionuclide Therapy Regimens**  
 Dr. Masha Maharaj  
*Umhlanga Molecular Imaging And Therapy. Centre of Excellence (South Africa)*
- 14:30 – 14:45** **Management of DTC beyond RAI**  
 Dr. Partha Choudhury  
*Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC) (India)*

- 14:45 – 15:00 Overview of Adverse reactions of radiopharmaceuticals, with focus in new agents**  
Dr. Raluca Mititelu  
*University of Medicine and Pharmacy Carol Davila Bucharest; Central University Emergency Military Hospital Bucharest (Romania)*
- 15:00 – 15:15 Rhenium for non-melanoma skin cancer**  
Dr. Mariela Agolti  
*Centro Medicina Nuclear Clínica Modelo (Argentina)*
- 15:15 – 15:30 What's next in prostate cancer theranostics: Beyond PSMA**  
Dr. Hossein Jadvar  
*University of Southern California (United States)*
- 15:30 – 15:45 Concepts to improve efficacy and safety of RLTs – next generation PSMA- & FAP-targeting Radiopharmaceuticals**  
Dr. Vasko Kramer  
*Positronpharma Sa (Chile)*

## Barahona Room 3

- 08:00 – 09:40 Pre-Congress Course: Radiopharmacy and Chemistry (1)**  
**Chairs:** Dr. Moralba Domínguez García (United States) and Dr. Mike Cornejo (United States)
- 08:00 – 08:30 Radioimmunotheranostics – Where are we and where are we going?**  
Prof. Jason Lewis  
*Sloan Kettering Institute (United States)*
- 08:30 – 09:00 Chelation Chemistry – Building Radiopharmaceuticals**  
Dr. David Bauer  
*University of Missouri (United States)*
- 09:00 – 09:30 Pretargeting approach**  
Dr. Natalia Herrero  
*PreTT (Denmark)*

**09:40 – 10:00 Morning Break**

- 10:00 – 12:00** **Pre-Congress Course: Radiopharmacy and Chemistry (2)**  
**Chairs:** Dr. Cindy Rodríguez (United States) and Miguel Ángel Ávila (Mexico)
- 10:00 – 10:35** **ABCs of alpha-based radiopharmaceuticals**  
 Dr. Janke Kleynhans  
*KuLeuven (Belgium)*
- 10:35 – 11:10** **Production and QC of Ac-225 labeled radiopharmaceuticals (GMP): From Basic radiochemistry to clinical studies**  
 Dr. Erik de Blois  
*Erasmus MC (The Netherlands)*
- 11:10 – 11:45** **Translating Radiopharmaceutical Science into Patient-Specific Dosimetry: Needs and Realities**  
 Prof. Mariella Adriana Teran Gretter  
*Universidad de la República (Uruguay)*
- 14:00 – 16:00** **Session: Nuclear Cardiology**  
**Chair:** Dr. Sonia Merlano-Gaitán (Colombia)
- 14:00 – 14:25** **Cardiac failure: amyloidosis, sarcoidosis and coronary disease: Clinical Aspects**  
 Dr. Gina González-Robledo  
*Fundación Santa Fe University Hospital (Colombia)*
- 14:25 – 14:50** **Nuclear cardiology in cardiac amyloidosis**  
 Dr. Gabriel Grossman  
*Hospital Moinhos de Vento (Brazil)*
- 14:50 – 15:15** **PET/CT and PET/MR in the evaluation and management of cardiac sarcoidosis**  
 Dr. Felipe Martínez  
*Mayo Clinic Arizona (United States)*
- 15:15 – 15:40** **AC-CT in myocardial perfusion SPECT to assess coronary calcium**  
 Dr. Fernando Mut  
*Italian Hospital (Uruguay)*
- 15:40 – 16:00** **SSTR imaging in inflammatory cardiomyopathy**  
 Dr. Chetan D Patel  
*Nuclear Medicine, All India Institute of Medical Sciences, New Delhi (India)*

## Barahona Room 4

**08:00 – 09:40 Pre-Congress Course: Internal Dosimetry in Clinical Practice: From Fundamentals to Advanced Tools and Applications (1)**  
Chair: Dr. Erick Mora (Costa Rica)

**08:00 – 08:20 Post-treatment Imaging and Dosimetry for Lu-177 Therapies**  
Dr. Carlos Uribe  
*Bc Cancer (Canada)*

**08:20 – 08:50 Dosimetry: Principles and Practical Approaches**  
Prof. Yuni Dewaraja  
*University of Michigan (United States)*

**08:50 – 09:10 Getting data ready for dosimetry (reconstruction, segmentation, registration, TAC fitting)**  
Dr. Juan Camilo Ocampo Ramos  
*Md Anderson Cancer Center (United States)*

**09:40 – 10:00 Morning Break**

**10:00 – 12:00 Pre-Congress Course: Internal Dosimetry in Clinical Practice: From Fundamentals to Advanced Tools and Applications (2)**  
Chair: Dr. Erick Mora (Costa Rica)

**10:00 – 10:20 Introduction to Dosimetry Software and Available Tools**  
Dr. Erick Mora  
*Universidad de Costa Rica (Costa Rica)*

**10:20 – 10:35 Case 1: 177Lu – Workflow and Quantification**  
Dr. Carlos Uribe  
*Bc Cancer (Canada)*

**10:35 – 10:50 Case 2: Alpha Dosimetry**  
Dr. Juan Camilo Ocampo Ramos  
*Md Anderson Cancer Center (United States)*

**10:50 – 11:10 Voxel-Level vs. Organ-Level Dosimetry What's Next?**  
Prof. Yuni Dewaraja  
*University of Michigan (United States)*

**11:10 – 11:35 Computational Nuclear Oncology: Towards Digital Twins**

Dr. Arman Rahmim  
*University of British Columbia (Canada)*

**11:35 – 12:00 Beyond dose: what drives treatment response in oncology?**

Dr. Mauro Namías  
*Fundación Centro Diagnóstico Nuclear (Argentina)*

**14:00 – 16:00 Session in Medical Physics: 25 Years of PET/CT: Past, Present, and the Hybrid Future**

**Chair:** Dr. Ana Maria Marques da Silva (Brazil)

**14:00 – 14:10 Opening Remarks: Welcome and session framing: 25 years of PET/CT and hybrid imaging today**

Dr. Ana Maria Marques da Silva  
*Usp & Mediima (Brazil)*

**14:10 – 14:30 25 years of PET/CT: A milestone perspective**

Prof. Thomas Beyer  
*Qimp Team, Medical University Vienna (Austria)*

**14:30 – 14:50 The transformative role of total body PET imaging**

Prof. Charalampos Tsoumpas  
*University Medical Center Groningen  
 (The Netherlands)*

**14:50 – 15:10 PET/MR challenges and clinical use towards multi-parametric quantification**

Prof. Nikolaos Karakatsanis  
*Weill Cornell Medical College (United States)*

**15:10 – 15:30 Artificial Intelligence in PET/CT: Replacing human intelligence in physics and medicine?**

Prof. Stefaan Vandenberghe  
*Ghent University (Belgium)*

**15:30 – 16:00 Panel Discussion: PET Imaging for diagnostics and theranostics: Recent Advancements, Challenges, and Future Prospects**

Prof. Thomas Beyer

*Qimp Team, Medical University Vienna (Austria)*

Prof. Stefaan Vandenberghe

*Ghent University (Belgium)*

Prof. Charalampos Tsoumpas

*University Medical Center Groningen  
(The Netherlands)*

Dr. Muhammad Umar Khan

*Al-Jahra Hospital (Kuwait)*

Dr. Ana Maria Marques da Silva

*Usp & Mediima (Brazil)*

Prof. Nikolaos Karakatsanis

*Weill Cornell Medical College (United States)*

## Arsenal Room

**08:00 – 09:40 WFNMB & SBMN Session: AI in Radiopharmacy, Oncology, and Cardiology**

**Chairs:** Dr. John Prior (Switzerland) and Dr. Paulo Almeida (Brazil)

**08:00 – 08:20 What is Implementation Science and Why It Matters for Bridging the AI Innovation-to-Application Gap in Nuclear Medicine**

Dr. Arman Rahmim

*University of British Columbia (Canada)*

**08:20 – 08:40 Artificial Intelligence in Cardiology**

Dr. Claudio Tinoco

*(Brazil)*

**08:40 – 09:00 Artificial Intelligence in Radiopharmacy**

Prof. Peter Scott

*University of Michigan (United States)*

**09:00 – 09:20 Artificial Intelligence in Oncology**

Dr. Dalton Anjos

*DASA (Brazil)*

09:40 – 10:00 Morning Break

14:00 – 16:00 **Oral Presentations I: Neurology, Radiopharmacy and Chemistry**

**Chairs:** Dr. Ana María Rey (Uruguay) and Iván Vega (Colombia)

**14:00 – 14:07 Diagnostic performance of  $^{18}\text{F}$ -choline PET/CT correlated with MRI in brain tumor recurrence: experience from an oncology hospital in Ecuador**

Dr. Christian Toalongo Moreno  
*Solca Guayaquil (Ecuador)*

**14:07 – 14:14 Diagnostic value of cisternoscintigraphy and CT cystenography in the detection of CSF leaks in patients with intracranial hypotension**

Dr. Sebastián Rojas Lara  
*Fundación Universitaria Sanitas (Colombia)*

**14:14 – 14:21 Beyond clinical assessment: The value of combined metabolic and dopaminergic mapping with PET/CT for the differential diagnosis of parkinsonian syndromes**

Dr. Abigail Arriaga Contreras  
*Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán (Mexico)*

**14:21 – 14:28 In vitro biological evaluation of a  $^{99\text{m}}\text{Tc}$  tricarbonyl complex derived from Erlotinib for molecular imaging in triple negative breast cancer**

Dr. María Emilia Tejería Pérez  
*Área Radioquímica/ Facultad de Química (Uruguay)*

**14:28 – 14:35 Results From a First-In-Human Phase I Trial of [ $^{68}\text{Ga}$ ]Ga-OncoCAIX in ccRCC: Safety, Dosimetry, Pharmacokinetics and Preliminary Diagnostic Performance**

Dr. Fabrizia Gelardi  
*Irccs San Raffaele Hospital (Italy)*

**14:35 – 14:42 Ampelomins radiolabelled with Tc-99m and F-18: Synthesis and functionalization of tracers for imaging infectious processes**

Prof. Mariella Adriana Teran Gretter  
*Universidad de la República (Uruguay)*

- 14:42 – 14:49 Radiosensitization of Theranostics for Pancreatic Ductal Adenocarcinoma**  
Dr. Moralba Domínguez García  
*Memorial Sloan Kettering Cancer Center (United States)*
- 14:49 – 14:56 Validation of an Alternative Analytical Technique for Determining the Radiochemical Purity of <sup>99m</sup>Tc-HMDP**  
Mr. Eliecer Cantillo  
*Fundación Valle Del Lili (Colombia)*
- 14:56 – 15:03 R1 from <sup>18</sup>F-PR04.MZ as a proxy for cerebral blood flow in degenerative parkinsonisms: comparison with <sup>15</sup>O-H<sub>2</sub>O PET/CT**  
Dr. Andrés Damián  
*Centro Uruguayo De Imagenología Molecular Cudim (Uruguay)*
- 15:03 – 15:10 Evaluation of cortical amyloid burden and tau deposition in cognitively normal and preclinical Alzheimer's disease through positron emission tomography**  
Mr. Phelipi Nunes Schuck  
*University of São Paulo (Brazil)*
- 15:10 – 15:17 Influence of EEG Discharges During FDG-PET Cerebral Metabolism Assessment in Patients with Pharmacoresistant Epilepsy**  
Dr. Valentino Méndez  
*Hospital de Clínicas (Uruguay)*
- 15:17 – 15:24 Evaluation of a murine model of metastatic castration resistant prostate cancer for combination radioligand therapy and immunotherapy**  
Dr. Cindy Rodríguez  
*Memorial Sloan Kettering Cancer Center (United States)*
- 15:24 – 15:31 Optimizing Pretargeted Radiotheranostics: From PET to Therapy**  
Mr. Mike Cornejo  
*Hunter College - CUNY (United States)*
- 15:38 – 15:45 Design and Astatination of Radioligands for the Pretargeted Delivery of Astatine-211**  
Mr. Mike Cornejo  
*Hunter College - CUNY (United States)*

## Pegasos Room

09:40 – 10:00 Morning Break

14:00 – 16:00 Workshop “Radioguided Tasting Menu”

**14:00 – 14:10 Starter: The Master Recipe of Radioguided Surgery**  
Dr. Sergi Vidal-Sicart  
*Clinic Barcelona (Spain)*

**14:10 – 14:25 Mise en Place: Know Your Tools**  
Dr. John Orozco Cortés  
*Dr. Peset University Hospital, Valencia (Spain)*

**14:25 – 14:55 Main Course: Precision Cooking**  
Dr. Luisa Fernanda León  
*Hospital Clínico San Carlos, Madrid (Spain)*

**14:55 – 15:10 Break / Discussion Between Stoves**

**15:10 – 15:35 Technical Pairing: From the Stove to the Operating Room**  
Dr. John Orozco Cortés  
*Dr. Peset University Hospital, Valencia (Spain)*

**15:35 – 15:55 Dessert: Radioguided Haute Cuisine**

**15:55 – 16:00 Final Discussion and Conclusions**

Pegasos Room

## Secretaría General

07:30 – 09:00 Asamblea Informativa de la Asociación Colombiana de Medicina Nuclear e Imágenes Moleculares

09:10 – 10:00 First ALASBIMN Meeting of Young Professionals

10:30 – 12:00 Meeting between ALASBIMN and Associations and Institutions

14:00 – 16:00 ALASBIMN Board of Directors and Presidents of National Societies Meeting & Meeting on ALASBIMN Committees

Secretaría General

## Auditorio Getsemaní

- 10:30 – 11:45** **CME: Plenary Session: Cardiology**  
**Chairs:** Dr. Felipe Martínez (United States) and Saule Karanauskas (Colombia)
- 10:30 – 10:45** **PET-CT in infective endocarditis**  
 Dr. Gabriel Grossman  
*Hospital Moinhos de Vento (Brazil)*
- 10:45 – 11:00** **Cardiac amyloidosis**  
 Dr. Maria Koutelou  
*Onassis Cardiac Surgery Center (Greece)*
- 11:00 – 11:20** **Quantitative cardiac PET in coronary artery disease**  
 Dr. Jamieson Bourque  
*University of Virginia (United States)*
- 16:30 – 17:45** **CME: Plenary Session: Technological Advances in Nuclear Medicine (1)**  
**Chairs:** Dr. Diana Páez (Austria) and Dr. Camilo García (France)
- 16:30 – 16:45** **Evaluation of treatment response in hematological tumors using PET-CT**  
 Dr. Cristina Matushita  
*InsCer Brain Institute of Rio Grande do Sul (Brazil)*
- 16:45 – 17:00** **The PET/CT Imaging Revolution: Going total-body and multi-parametric**  
 Prof. Thomas Beyer  
*Qimp Team, Medical University Vienna (Austria)*
- 17:00 – 17:15** **AI in Radiopharmacy**  
 Prof. Peter Scott  
*University of Michigan (United States)*
- 17:15 – 17:30** **Reimagining Theranostics: From AI-Enhanced Dosimetry to Digital Twins in Nuclear Oncology**  
 Dr. Arman Rahmim  
*University of British Columbia (Canada)*

- 17:45 – 18:15** **Plenary Session: Technological Advances in Nuclear Medicine (2)**  
**Chair:** Dr. Diana Páez (Austria) and Dr. Camilo García (France)
- 17:45 – 18:00** **Role of long-axial field-of-view PET/CT in the evolution of Theranostics**  
 Dr. Carlos Uribe  
*Bc Cancer (Canada)*
- 18:00 – 18:15** **To be confirmed**  
 Dr. Jeffrey Yap  
*Huntsman Cancer Institute (United States)*

## Barahona Room 1

- 08:00 – 10:00** **CME: Session: PET CT in Hematological Disease**  
**Chair:** Prof. Adriana Quiteria Buitrago Gómez (Colombia) and Dr. Cristina Matushita (Brazil)
- 08:00 – 08:20** **Chimeric Antigen Receptor T-Cell Therapy: clinical aspects**  
 Prof. Marc André  
*CHU UCL Namur (Belgium)*
- 08:25 – 08:50** **Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts**  
 Dr. Vanessa Murad  
*University Medical Imaging Toronto (Canada)*
- 08:50 – 09:15** **Impact of metabolic tumor volume, total glycolysis and Deauville criteria in the assessment of treatment response in Hodgkin's lymphoma**  
 Dr. Miguel Ángel Olarte Casas  
*UNAM (Mexico)*
- 09:15 – 09:40** **PET-CT in multiple myeloma**  
 Dr. Nagabhushan Seshadri  
*Liverpool University Hospital (United Kingdom)*
- 14:00 – 16:00** **CME: Session: Molecular Imaging in Neurology**  
**Chairs:** Dr. Sara Ramírez (Colombia) and Iván Díaz (Mexico)
- 14:00 – 14:25** **PET imaging biomarkers in cognitive decline**  
 Prof. Javier Arbizu  
*Clínica Universidad de Navarra (Spain)*

- 14:25 – 14:50 Care Pathway for Cognitive Disorders**  
Prof. Satoshi Minoshima  
*University of Utah (United States)*
- 14:50 – 15:15 FET PET-CT in CNS tumors**  
Dr. Iván Vega  
*Clínica Las Américas Auna; Clínica Central del Eje (Colombia)*
- 15:15 – 15:40 Molecular PET imaging in parkinsonian syndromes**  
Prof. Javier Arbizu  
*Clínica Universidad de Navarra (Spain)*
- 15:40 – 16:00 Molecular and multimodal neuroimaging in drug-resistant epilepsy**  
Dr. Rodolfo Ferrando  
*Nuclear Medicine Center, Clinics Hospital, Universidad de la República and Uruguayan Center for Molecular Imaging (Uruguay)*

## Barahona Room 2

- 08:00 – 10:00 WARMTH Symposia (ISRT). Novel Therapies II**  
**Chair:** Dr. Partha Choudhury (India) and Prof. Irene Virgolini (Austria)
- 08:05 – 08:20 A Patient Path to Radioligand Therapy: Routes to Access**  
PhD. Efrain Perini  
*Oncidium Foundation (Belgium)*
- 08:20 – 08:35 Exploring Novel Radionuclides for Targeted Alpha and beta Therapy**  
Dr. Cecilia Carreras  
*Hospital Angeles Health System (Mexico)*
- 08:35 – 08:50 Clear Target: Advancing Imaging and Therapy in Clear Cell Renal Carcinoma**  
Prof. Michael S. Hofman  
*Peter MacCallum Cancer Centre (Australia)*
- 08:50 – 09:20 FAPI – Targeted Radiotherapy in Pancreatic Cancer: Advances, Challenges, and Future**  
Prof. Richard Baum  
*Curanosticum Wiesbaden-Frankfurt (Germany)*

14:00 – 16:00

**Session: Nuclear Medicine-Guided Procedures**

**Chairs:** Miguel Ángel Olarte Casas (Mexico)  
and Dr. Paulo Almeida (Brazil)

14:00 – 14:20

**Sentinel node imaging and radioguided surgery**

Dr. Sergi Vidal-Sicart  
*Clinic Barcelona (Spain)*

14:20 – 14:40

**Applications of artificial intelligence in the field of radioguided and robotic surgery**

Dr. John Orozco Cortés  
*Dr. Peset University Hospital, Valencia (Spain)*

14:40 – 15:00

**Radiotracing of peripheral pulmonary lesions guided by electromagnetic navigation: a novel localization technique**

Dr. Luisa Fernanda León  
*Hospital Clínico San Carlos, Madrid (Spain)*

15:00 – 15:20

**SPECT-CT lung volume reduction surgery**

Prof. Simin Dadparvar  
*Penn State Hershey Medical Center (United States)*

**Barahona Room 3**

08:00 – 10:00

**ALASBIMN: Radiopharmacy (1)**

**Chair:** Dr. Ana María Rey (Uruguay)

08:00 – 08:45

**Enhancing the Efficacy of Targeted Radionuclide Therapy Through Radionuclide Selection and Combination Strategies**

Dr. Martin Behe  
*Paul Scherrer Institut (Switzerland)*

08:45 – 09:05

**Is research on <sup>99m</sup>Tc still relevant? Exploring its chemistry to find the answer**

Dr. María Emilia Tejería Pérez  
*Área Radioquímica/ Facultad de Química (Uruguay)*

09:05 – 09:25

**Advancing the <sup>177</sup>Lu Therapeutic Landscape: From Repurposing Strategies to the Validation of Novel Vectors and Chelators**

Dr. Ana Clarisa López  
*Cnea (Argentina)*

**09:25 – 09:45 Radiopharmaceuticals in the Real World: What the Data Reveal Beyond Clinical Trials – A Brazilian Experience**  
Mrs. Priscila Pujatti  
*National Cancer Institute (Brazil)*

**14:00 – 16:00 ALASBIMN: Radiopharmacy (2)**  
Chair: Dr. David Bauer (United States)

**14:00 – 14:25 Considerations on solid vs liquid targets for the production of Ga-68 with cyclotrons (Solid targets)**  
Dr. Miguel Ángel Ávila  
*National Autonomous University of Mexico (UNAM) (Mexico)*

**14:25 – 14:45 Considerations on solid vs liquid targets for the production of Ga-68 with cyclotrons (Liquid targets)**  
Dr. Javier Giglio  
*Cudim (Uruguay)*

**14:45 – 15:05 Current status and availability of alpha radionuclide production in the world**  
Dr. Janke Kleynhans  
*KuLeuven (Belgium)*

**15:05 – 15:25 Clinical Translation of Radiometallated Agents in Oncology: Considerations and Lessons Learnt**  
Dr. Serge Lyashchenko  
*Memorial Sloan Kettering Cancer Center (United States)*

Dr. Moralba Domínguez García  
*Memorial Sloan Kettering Cancer Center (United States)*

**15:25 – 15:45 Preclinical studies for therapeutic evaluation in neurosciences**  
Prof. Daniele de Paula Faria  
*University of Sao Paulo, School of Medicine (Brazil)*

## Barahona Room 4

- 08:00 – 10:00 Technologists Symposia (1)**  
**Chair:** Dr. Cindy Davis (South Africa)
- 08:00 – 08:30 Key aspects of molecular imaging in oncology: FDG vs FAPI**  
 Dr. Pamela Casanova  
*Gamanuclear (Colombia)*
- 08:30 – 09:00 Cardiac PET MRI with F18 FAPI**  
 Lic. Bruno Bernat  
*Fundación Escuela de Medicina Nuclear (Fuesmen) (Argentina)*
- 09:00 – 09:30 Integration and quantitative analysis of SUV in labeled leukocyte scintigraphy for prosthetic knee infection**  
 Señor Carlos Mario Ramírez  
*Clínica de Occidente de Cali (Colombia)*
- 09:30 – 10:00 CZT**  
 Lic. Martin Lema  
*Cyclomedica (Argentina)*
- 14:00 – 16:00 Technologists Symposia (2)**  
**Chairs:** Dr. Juan Lubo Marín (Colombia)  
 and Prof. Juan P. Oliva (Cuba)
- 14:00 – 14:25 18F-FES Imaging in ER + Breast Cancer**  
 Dr. Tina Buehner  
*University of Arizona - Tucson (United States)*
- 14:25 – 14:50 From Diagnosis to Therapy: The Journey of PSMA in Prostate Molecular Imaging**  
 Mr. Ismael Cordero  
*CUDIM (Uruguay)*
- 14:50 – 15:20 Advances in Molecular Imaging: Enhancing the Oncology Patient Journey—From Diagnosis to Cure: Technological Solutions for Personalized Theranostics**  
 Dr. Solange Nogueira  
*GE HeathCare (Brazil)*
- 15:20 – 15:40 Beta-amyloid and Tau PET imaging in Alzheimer's disease**  
 Prof. Julie Bolin  
*Gateway Community College (United States)*

## Arsenal Room

### 08:00 – 10:00 Oral Presentations 2: Physics and Technology

**Chairs:** Lic. Juan Lubo Marín (Colombia)  
and Dr. Nathaly Barbosa (Colombia)

- 08:00 – 08:07 Combining deep learning and kinetic modeling for cerebral PET parametric imaging with reduced-time dynamic acquisitions**  
Lic. Santiago Burgos  
*Universidad Nacional Autónoma de México (Mexico)*
- 08:07 – 08:14 High throughput scanning with a vertical and compact Walk-Through flat panel PET**  
Prof. Stefaan Vandenberghe  
*Ghent University (Belgium)*
- 08:14 – 08:21 Internal Dosimetry Calculation for PET/CT with <sup>18</sup>F-PSMA-1007 Using OpenDose Software**  
Prof. Kelly Sandoval Sandoval  
*Fundación Arturo López Pérez (Chile)*
- 08:21 – 08:28 Quantitative Evaluation of Scatter Correction Strategies in Long Axial Field-of-View PET/CT**  
Dr. Mohammadreza Teimoorisichani  
*Siemens Medical Solutions USA Inc (United States)*
- 08:28 – 08:35 A Quantitative CT-less Reconstruction Workflow for Long-axial Field-of-view PET Scanners with Enhanced Scaling**  
Dr. Mohammadreza Teimoorisichani  
*Siemens Medical Solutions USA Inc (United States)*
- 08:35 – 08:42 High-Precision PET/CT: Optimization and Quality strategies led by the Nuclear Medicine Technologist**  
Sra. Andrea Milena Bautista Beltrán  
*Clínica de Marly (Colombia)*
- 08:42 – 08:49 Brain MRI-guided PET Reconstruction in a New PET/MRI System with <200ps TOF resolution**  
Dr. Jorge Cabello  
*Siemens Healthineers (United States)*
- 08:49 – 08:56 Colombian Guide for the support of Radiological Events in Nuclear Medicine and Radiopharmacy**  
Mrs. Lorena Sandoval Castillo  
*Asociación Colombiana de Física Médica /  
Clínica del Country (Colombia)*

- 08:56 – 09:03 Comparison of Patlak imaging with SUV imaging in metastatic uveal melanoma patients with a long axial field-of-view (LAFOV) PET/CT**  
Dr. Leyun Pan  
*German Cancer Research Center (Germany)*
- 09:03 – 09:10 Clinical validation of deep learning denoising for low-count PET/CT: preserving SUV accuracy and image quality**  
Dr. Yamila Rotstein Habarnau  
*Fundación Centro Diagnóstico Nuclear (Argentina)*
- 09:10 – 09:17 Rapid scan assessment with non-quantitative FastPET: Generalizability to different tracers and count levels**  
Naveen Murthy  
*Siemens Healthineers (United States)*
- 09:17 – 09:24 Deep learning-based dose estimation for radionuclide therapy: a feasibility study**  
Dr. Yamila Rotstein Habarnau  
*Fundación Centro Diagnóstico Nuclear (Argentina)*
- 09:24 – 09:31 Assessment of the impact of gastrointestinal motion on PET quantification due to mismatched CT**  
Dr. Giordana Salvi De Souza  
*UFRGS (Brazil)*
- 09:31 – 09:38 Optimization of pet/ct acquisition parameters for pregnant patients: phantom study with reduced dose and preserved image quality**  
Mr. Yann Cras  
*Gustave Roussy (France)*
- 09:38 – 09:45 Implementation of Innovative Toilet Filtration Systems for Radionuclide Therapy Effluents: First Latin American Clinical Experience**  
Lic. Yesenia Saldierna Martínez  
*Hospital Ángeles Centro Sur (Mexico)*
- 09:45 – 09:52 Semiquantitative difference in the uptake of the pineal gland of [18F]fluorodopamine in patients with Parkinson's disease versus atypical parkinsonism**  
Dr. Kinari Ortega  
*Unam (Mexico)*

14:00 – 16:00

**Oral presentations 3: Cardiology, Infection and Inflammation**

**Chair:** Dr. Sonia Simona Traverso (Argentina)  
and Dr. Edel Noriega (Spain)

- 14:00 – 14:07** **Cocaine-dependent patients with depressive symptoms and suicide risk studied with brain perfusion SPECT and systemic inflammatory markers**  
Dr. Teresa Massardo  
*Hospital Clínico Universidad de Chile (Chile)*
- 14:07 – 14:14** **Radiosynoviorthesis with Erbium-169 Following Surgery for Ankle Pigmented villonodular synovitis: A Rare Disease Series with more than 5 Year Follow-Up**  
Prof. Ioannis Iakovou  
*Aristotle University of Thessaloniki (Greece)*
- 14:14 – 14:21** **Deep-learning-based positron range correction (PRC) for Rb-82 cardiac PET**  
Dr. Jorge Cabello  
*Siemens Healthineers (United States)*
- 14:21 – 14:28** **Analysis of the Prognostic Value of Myocardial Perfusion Imaging – SPECT/CT Stratified by the AHA/ASCN 2021 Risk Algorithm**  
Dr. Sebastián Rojas Lara  
*Fundación Universitaria Sanitas (Colombia)*
- 14:28 – 14:35** **Towards a new classification of therapeutic response in IgG4-related disease: A cluster approach based on 18F-FDG PET/CT**  
Dr. Miguel Ángel Corza Ayala  
*Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico)*
- 14:35 – 14:42** **[99mTc]Tc-iFAP SPECT/CT as a new radiotracer for the evaluation of lesions in IgG4-related disease: Comparison with 18F-FDG PET/CT**  
Dr. Miguel Ángel Corza Ayala  
*Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico)*

- 14:42 – 14:49 Nitrate-enhanced technetium-99m-sestamibi single photon emission tomography for myocardial viability assessment: eleven year single center experience**  
Dr. Eduardo Lischinsky  
*CMNIM, Hospital de Clínicas Dr. Manuel Quintela Universidad de la República (Uruguay)*
- 14:49 – 14:56 Myocardial perfusion patterns and ventricular function in patients with chagas disease, analysis at a regional reference center in eastern Colombia**  
Dr. Marvin Holman Anderson Achicanoy Botina  
*Universidad Autónoma de Bucaramanga (UNAB) (Colombia)*
- 14:56 – 15:03 Assessment of CCR2-Related Inflammatory Activity in Abdominal Aortic Aneurysms with 99mTc-HYNIC-CCR2-L and SPECT/CT**  
Dr. Jorge Rodríguez  
*Instituto Nacional de Ciencias Médicas y Nutrición (Mexico)*
- 15:03 – 15:10 SPECT/CT with [99mTc]Tc-UBI 29-41 in challenging-to-diagnose infections: clinical concordance and impact on redefining the initial diagnosis**  
Dr. Hernando Andrés Benavides Jiménez  
*Fundación Universitaria Sanitas (Colombia)*
- 15:10 – 15:17 Splenic uptake in dipyridamole stress and rest tc-99m mibi spect: a potential vasodilatory marker**  
Dr. Paula Aristov  
*Servicio Medicina Nuclear, Hospital de Clínicas (Uruguay)*
- 15:17 – 15:24 Cannabidiol prevents age-related cognitive decline and neuroinflammation, and enhances brain metabolism in a Down syndrome animal model**  
Dr. Lidia Spelta  
*INRAD, HCFMUSP (Brazil)*
- 15:24 – 15:31 Quantitative 99mTc-PYP SPECT/CT in ATTR-CA: head-to-head MBR, LV/bone and SUVmax with near-perfect discrimination**  
Mr. Luciano Santos  
*Consultorio de Medicina Nuclear FFP (Uruguay)*

**15:31 – 15:38 Myocardial perfusion imaging: When is not just supine, not just prone**

Dr. Romina Lorena Romero  
*Hospital Británico de Buenos Aires (Argentina)*

**15:38 – 15:45 Standardized Formulation of a Business Case for a PET-CT Nuclear Medicine Service in Colombia**

Dr. Saule Karanauskas  
*Medicina Nuclear Diagnóstica Sas (Colombia)*

## Pegasos Room

---

**08:00 – 10:00 Workshop: Molecular Brain Imaging of Dementia: Read with Expert**

**Chair:** Dr. Sara Ramírez

Prof. Satoshi Minoshima  
*University of Utah (United States)*

**14:00 – 16:00 Medical Physics Workshop: Practical Dosimetry Using MIRDSOFT**

**Chair:** Dr. Erick Mora (Costa Rica)  
 and Dr. Nathaly Barbosa (Colombia)

**14:00 – 14:30 MIRDSOFT overview: MIRD; MIRDcalc; MIRDfit; MIRDct; MIRDy90; MIRDpvc; MIRDspecs; MIRDcell**

Dr. Juan Camilo Ocampo Ramos  
*Md Anderson Cancer Center (United States)*

**14:30 – 15:00 PowerPoint walkthrough (guided): MIRDfit; MIRDcalc; MIRDct; MIRDpvc (workflow and key inputs/outputs)**

Dr. Juan Camilo Ocampo Ramos  
*Md Anderson Cancer Center (United States)*

**15:00 – 16:00 Hands-on self-examples (case-based): distribute Excel practice worksheets: MIRDfit examples. MIRDcalc examples. MIRDcalc examples. MIRDpvc examples. MIRDct examples**

Dr. Juan Camilo Ocampo Ramos  
*Md Anderson Cancer Center (United States)*

## Secretaría General

---

**14:00 – 16:00 WFNMB Assembly**

## Auditorio Getsemaní

### 08:00 – 10:00 **CME: Session: Theranostics in Prostate Cancer**

**Chair:** Dr. Marcus Roef (The Netherlands)

#### 08:00 – 08:20 **Sequencing in castration-resistant prostate adenocarcinoma**

Dr. Ray Maneh

*Sociedad de Oncología y Hematología del César (Colombia)*

#### 08:20 – 08:40 **Redefining Prostate Cancer Staging and Management in the era of PSMA PET CT**

Dr. Partha Choudhury

*Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC) (India)*

#### 08:40 – 09:00 **Biology and Clinical Trials in Oligometastatic Prostate Cancer**

Dr. Hossein Jadvar

*University of Southern California (United States)*

#### 09:00 – 09:20 **Radium 223 in prostate cancer**

Dr. John Buscombe

*None (United Kingdom)*

#### 09:20 – 09:40 **Alpha therapy in prostate cancer**

Dr. Joseph R. Osborne

*Weill Cornell Medicine (United States)*

#### 09:40 – 10:00 **Emerging trends in prostate cancer theranostics: what's hot in the last year?**

Prof. Michael S. Hofman

*Peter MacCallum Cancer Centre (Australia)*

### 09:40 – 10:00 **Morning Break** ☕

### 10:30 – 11:45 **CME: Plenary Session: Thyroid Cancer**

**Chairs:** Dr. John Buscombe (United Kingdom) and Dr. Melissa Álvarez (Colombia)

#### 10:30 – 10:40 **From pathology to the administration of radioactive iodine, adjusted to the ATA 2025 guidelines**

Dr. Paula A. Rodríguez

*Fundación Santa Fe de Bogotá (Colombia)*

- 10:40 – 10:50 ATA 2025**  
Dr. Savvas Frangos  
*World Federation of Nuclear Medicine and Biology (Cyprus)*
- 10:50 – 11:00 Role of rTSH in the management of differentiated thyroid cancer**  
Dr. Partha Choudhury  
*Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC) (India)*
- 11:00 – 11:10 Management of metastatic differentiated thyroid cancer (DTC)**  
Prof. Salah Eddine Bouyoucef  
*Faculty of Medicine/CHU Bab El Oued (Algeria)*
- 11:10 – 11:20 Molecular Theranostics in Thyroid Cancer**  
Prof. Sze Ting Lee  
*Austin Health (Australia)*
- 11:20 – 11:30 Personalized I-131 therapy for metastatic thyroid cancer: A dosimetry-driven approach**  
Dr. Munir Ghesani  
*United Theranostics (United States)*
- 16:30 – 18:30 CME: Plenary Session: Prostate cancer**  
**Chairs:** Dr. Homer A. Macapinlac (United States)  
and Dr. Marcus Roef (The Netherlands)
- 16:30 – 16:50 Molecular and radiobiological mechanisms in radioligand therapy in prostate cancer**  
Dr. Osvaldo García-Pérez  
*National Cancer Institute (Mexico)*
- 16:50 – 17:10 Evaluation of treatment response in prostate cancer in the era of radioligand therapy**  
Dr. Joseph R. Osborne  
*Weill Cornell Medicine (United States)*
- 17:10 – 17:40 From Vision to Victory: Unleashing Theranostics in Prostate Cancer**  
Prof. Michael S. Hofman  
*Peter MacCallum Cancer Centre (Australia)*
- 17:40 – 18:00 Simplifying <sup>177</sup>Lu-PSMA Dosimetry: Towards Practical and Personalized Therapy**  
Prof. Yuni Dewaraja  
*University of Michigan (United States)*

## Barahona Room 1

### 08:00 – 10:00 **Session: Lung Cancer**

**Chairs:** Dr. Augusto Llamas Olier (Colombia)  
and Prof. Raúl Cabrejas (Argentina)

#### 08:00 – 08:20 **CT and FDG PET/CT in lung nodule**

Prof. Simin Dadparvar  
*Penn State Hershey Medical Center (United States)*

#### 08:20 – 08:40 **FDG PET/CT in the staging of lung cancer**

Dr. Munir Ghesani  
*United Theranostics (United States)*

#### 08:40 – 09:00 **PET/CT beyond FDG in lung cancer**

Dr. Osvaldo García-Pérez  
*National Cancer Institute (Mexico)*

#### 09:00 – 09:20 **Evaluation of response to immunotherapy with FDG PET/CT in lung cancer**

Dr. Camilo García  
*Gustave Roussy (France)*

#### 09:20 – 09:40 **Theranostics in lung cancer**

Dr. Homer A. Macapinlac  
*The University of Texas Md Anderson Cancer Center (United States)*

### 14:00 – 16:00 **CME: Session: Molecular Imaging in Solid Tumors**

**Chairs:** Dr. Raluca Mititelu (Romania)  
and Dr. Augusto Llamas Olier (Colombia)

#### 14:00 – 14:20 **PET/CT in Soft Tissue Sarcomas**

Prof. Elba Etchebehere  
*Brazilian Society Of Nuclear Medicine and Molecular Imaging (Brazil)*

#### 14:20 – 14:40 **PET and Theranostics in Breast Cancer**

Dr. Gisela Estrada  
*ALASBIMN (Mexico)*

#### 14:40 – 15:00 **Molecular Breast Imaging for Breast Screening**

Dr. Gaiane Rauch  
*Ut Md Anderson Cancer Center (United States)*

#### 15:00 – 15:20 **PET/CT Imaging of Gastrointestinal Cancers**

Prof. Rakesh Kumar  
*All India Institute of Medical Sciences (AIIMS) (India)*

- 15:20 – 15:40** **Theranostic trials in solid tumor**  
Prof. Medhat Osman  
*Saint Louis University (United States)*
- 15:40 – 16:00** **PET Quantification in Oncology in the Era of Total-Body PET and Personalized Radiopharmaceutical Therapy**  
Prof. Nikolaos Karakatsanis  
*Weill Cornell Medical College (United States)*

## Barahona Room 2

- 08:00 – 10:00** **Oral Presentations 4: Therapy and Radioguided Procedures**  
**Chairs:** Dr. Adriana Quiteria Buitrago Gómez (Colombia) and Dr. Sandra Caro (Colombia)
- 08:00 – 08:07** **[<sup>177</sup>Lu]Lu-DOTA-ATWLPPR/(D-Lys6-LHRH) peptide heterodimer as a potential theragnostic agent for prostate and breast cancer**  
Dr. Ximena Camacho  
*Universidad de la República (Uruguay)*
- 08:07 – 08:14** **Targeted ROR1 protein degradation combined with PET imaging reveals the role of ROR1 in overcomes EGFR Resistance in NSCLC**  
Mr. Bo Mei  
*Peking University Cancer Hosiptal (China)*
- 08:14 – 08:21** **Preclinical evaluation of <sup>212</sup>Pb-labeled CXCR4 peptides for targeted alpha therapy in colorectal carcinomatosis**  
Mr. Richard Whiteside  
*The University of Missouri (United States)*
- 08:21 – 08:28** **Intraoperative Sentinel Lymph Node Mapping with Dual Modality (Radioisotopic/Optical) Using <sup>99m</sup>Tc-ICG Nanocolloid: Improved Precision and Overcoming Clinical Limitations**  
Mrs. Carolina Furtado Prieto  
*UA Medicina Nuclear e Imagenología Molecular, Centro de Investigaciones Nucleares - Universidad de la República (Uruguay)*

- 08:28 – 08:35 Intraoperative near-infrared lymphatic mapping in thyroid cancer using intrathyroidal indocyanine green**  
Mrs. Carolina Furtado Prieto  
*UA Medicina Nuclear e Imagenología Molecular, Centro de Investigaciones Nucleares – Universidad de la República (Uruguay)*
- 08:35 – 08:42 Diagnostic Accuracy of Robotic Arm assisted Real time PET-CT guided Biopsy of Abdomino-pelvic lesions including Retroperitoneal lesions**  
Dr. Arun Ravi John  
*Command Hospital Air Force (India)*
- 08:42 – 08:49 Bridging Vision and Practice: The Journey to Implementing a Theranostics Centre at the University Health Network in Toronto, Canada**  
Dr. Luke Brzozowski  
*University Health Network (Canada)*
- 08:49 – 08:56 Real-world efficacy: first prospective study in Argentina of the effectiveness and safety of <sup>177</sup>Lu-DOTATATE in GEP-NET**  
Lic. Mariano Portillo  
*Instituto Alexander Fleming (Argentina)*
- 08:56 – 09:03 Intraoperative metabolic assessment (PET-CT) of surgical margins in breast cancer: a novel challenge in oncologic surgery**  
Dr. John Orozco Cortés  
*Dr. Peset University Hospital, Valencia (Spain)*
- 09:03 – 09:10 Freehand-SPECT augmented reality navigation compared with planar scintigraphy for sentinel lymph node biopsy in breast cancer**  
Dr. John Orozco Cortés  
*Dr. Peset University Hospital, Valencia (Spain)*
- 09:10 – 09:17 First experience with molecular surgery in pancreatic and hepatic cancer using PET radiopharmaceuticals**  
Dr. John Orozco Cortés  
*Dr. Peset University Hospital, Valencia (Spain)*

- 09:17 – 09:24** **Impact of fixed SUV thresholds on lesion segmentation in PSMA PET/CT: methodological implications for RECIST response assessment to Lu177-PSMA-617 therapy**  
Mr. Yann Cras  
*Gustave Roussy (France)*
- 09:24 – 09:31** **Limitations of applying the Hänscheid single-time-point method to <sup>177</sup>Lu-PSMA-617 organ dosimetry: toward PSMA-specific simplified protocols**  
Mr. Yann Cras  
*Gustave Roussy (France)*
- 09:31 – 09:38** **Selection of Patients for Lutetium-177 DOTATATE Therapy Using Tc-99m HYNIC-TOC Scintigraphy: Preliminary Experience in a Peruvian Center**  
Dr. Shirley Alarcón  
*Clínica Ricardo Palma (Perú)*
- 09:38 – 09:45** **Biochemical Variability in the Response to [<sup>177</sup>Lu]Lu-IPsma in Heavily Pretreated Patients: Real-World Experience**  
Dr. Edgar Hernández  
*Incan (Mexico)*

**14:00 – 16:00** **ASNC Nuclear Cardiology Workshop for Physicians: PET and SPECT Myocardial Flow Quantification**

**Chair:** Dr. Gabriel Grossman (Brazil)

**Evidence of clinical applications for myocardial flow quantification**

Dr. Panithaya Chareonthaitawee  
*Mayo Clinic (United States)*

**Presentation and discussion of PET cases**

Dr. Jamieson Bourque  
*University of Virginia (United States)*

**Presentation and discussion of CZT cases**

Dr. Gabriel Grossman  
*Hospital Moinhos de Vento (Brazil)*

## Barahona Room 3

### 08:00 – 10:00 ISORBE Symposia

Chair: Dr. Victoria Soroa (Argentina)

#### 08:00 – 08:35 The evolution of leukocyte labeling in the diagnosis of infections

Prof. Madhukar Thakur

*Thomas Jefferson University/k. Comp. Cancer Ctr.r. (United States)*

#### 08:35 – 09:10 Radiomolecules in infection and inflammation in Argentina

Prof. Victoria Soroa

*Imat, Cnea, INTECNUS (Argentina)*

#### 09:10 – 09:45 Labeled leukocytes in prosthetic joint infections: Clinical cases and challenges

Dr. Edel Noriega

*University Hospital of Guadalajara (Spain)*

#### 09:45 – 10:00 PET/CT in spondylodiscitis: Accurate diagnosis and clinical management

Dr. Edel Noriega

*University Hospital of Guadalajara (Spain)*

### 14:00 – 16:00 ALASBIMN: Cyclotron Symposium

## Barahona Room 4

### 08:00 – 10:00 Technologists Symposia (3): Quantitative Imaging: From Harmonization to Clinical Metrics

Chair: Prof. Margarita Núñez

#### 08:00 – 08:30 Harmonization

Prof. Marco Coca

*Medscan Nuclear Medicine And PET/CT Center (Chile)*

#### 08:30 – 09:00 Quantitative Parameters: Metrics, Dosimetry, and Clinical Decision-Making

Mrs. Nathaly Barbosa

*Centro de Tratamiento e Investigación Sobre Cáncer (Colombia)*

**09:00 – 09:30** **Advanced Quantification Techniques in PET/SPECT: From Denoising to Deep Learning**  
Dr. Mauro Namías  
*Fundación Centro Diagnóstico Nuclear (Argentina)*

**09:30 – 10:00** **Technological Advances for Precise Quantification with TOF-PET: From System Design to Clinical Metrics**  
Dr. Kohei Hanaoka  
*KINDAI University (Japan)*

**14:00 – 16:00** **Technologists Symposia (4)**  
**Chair:** Dr. Tina Buehner (United States)

**14:00 – 14:25** **Theragnostics in NETs: a single molecular target, evidence and practice**  
Lic. Mariano Portillo  
*Instituto Alexander Fleming (Argentina)*

**14:25 – 14:50** **Ac225**  
Mrs. Cindy Davis  
*Nuclear Medicine Research Infrastructure Centre (South Africa)*

**14:50 – 15:20** **Astatine-211 for Cyclotron-Based Alpha Theranostics**  
Prof. Tadashi Watabe  
*The University of Osaka (Japan)*

**15:20 – 15:50** **Do we need dosimetry?**  
Dr. Seval Beykan Schürle  
*Itm Oncologics (Germany)*

## Arsenal Room

**12:15 – 14:15** **Oral Presentations 5: Oncology 1 (NETs and Prostate)**  
**Chair:** Dr. Rodrigo Cárdenas Perilla (Colombia)  
and Dr. Nathalie Hernández (Colombia)

**12:15 – 12:22** **Role of 18F-PSMA-(Pylclari) and 68Ga-PSMA-11 PET-CT in the staging of high-risk prostate cancer**  
Dr. Carlos Andrés Tapias Mesa  
*Institut de Diagnostic Per La Ima The Idi (Spain)*

- 12:22 – 12:29** **99mTc-HYNIC-iPSMA SPECT/CT in Prostate Cancer: A Real-World Data Multicentric Study in 457 Mexican Patients**  
Dr. Joel Vargas Ahumada  
*Imagenología Diagnóstica (Mexico)*
- 12:29 – 12:36** **Prospective head-to-head comparison of 18F-PSMA -1007 and 18F-DCFPyl PET/CT for primary skeletal staging in high risk prostate cancer**  
Dr. Marko Seppänen  
*Turku University Hospital (Finland)*
- 12:36 – 12:43** **Validation of PET/CT with 18F-NOTA-Oc and 18F-FDG for obtaining the “NETPET score” as a prognostic biomarker in neuroendocrine neoplasms**  
Dr. Francisco Jesús Solano Caballero  
*Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico)*
- 12:43 – 12:50** **[99mTc]Tc-HYNIC-PEG4-ATWLPPR/Tricine peptide as a potential diagnostic agent for prostate cancer: In vitro evaluation**  
Mrs. Carolina Perroni Zanoniani  
*Universidad de la República (Uruguay)*
- 12:50 – 12:57** **Results from a Prospective Phase I Clinical Trial on [68Ga]Ga-OncoACP3 in Prostate Cancer: Safety, Dosimetry, Pharmacokinetics and Diagnostic Performance**  
Dr. Cristiano Pini  
*Vita-salute San Raffaele University (Italy)*
- 12:57 – 13:04** **Prostate Tumor Volume by 68Ga-PSMA PET/CT as a Predictor of Lymph Node Metastases in High-Risk Prostate Cancer**  
Dr. Angie Paola Llanos Cuéllar  
*Fundación Universitaria Sanitas (Colombia)*
- 13:04 – 13:11** **Usefulness of Fluoride PET CT 18F-Alf Nota on suspicion of well-differentiated neuroendocrine tumors (NETs)**  
Dr. Francisco Gómez  
*Hospital Clínico Universidad de Chile (Chile)*
- 13:11 – 13:18** **[18F]SiTATE in neuroendocrine neoplasia (NEN): first Latin America experience in prostate, lung and colon NEN patients**  
Dr. Emiliano Michel Sánchez  
*Oncología San José (Mexico)*

- 13:18 – 13:25** **Clinical Impact Of 18F-PSMA-1007 PET/CT In The Evaluation of Prostate Cancer Patients: Analysis of 511 Patients In Different Clinical Scenarios**  
Dr. Gerardo Dos Santos  
*Cudim (Uruguay)*
- 13:25 – 13:32** **Magnitude of change in radiotherapy planning in biochemical recurrence of prostate cancer. From theoretical planned to definitive treatment post-PET-TC PSMA**  
Dr. Pedro José Plaza López  
*Hospital del Mar (Spain)*
- 13:32 – 13:39** **Biochemical Response Following PSMA-1007 Metabolic Imaging-Guided Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy**  
Dr. Pedro José Plaza López  
*Hospital del Mar (Spain)*
- 13:39 – 13:46** **Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET-CT in prostate cancer patients with occult biochemical recurrence with low PSA values**  
Dr. Pedro José Plaza López  
*Hospital del Mar (Spain)*
- 13:46 – 13:53** **Non-informative [18F]FDG PET/CT studies and rescheduling times as quality indicators in a Latin American reference center**  
Mr. Ismael Cordero  
*CUDIM (Uruguay)*
- 13:53 – 14:00** **Synergy in sight: fusing PSMA PET/CT and mpMRI parameters to enhance prostate cancer risk stratification**  
Dr. Eva Lorena Valadez Montero  
*Centro Médico ABC (Mexico)*

## Secretaría General

- 14:00 – 16:00** **From WHA78.13 on Strengthening Medical Imaging Capacity to Action – Stakeholders Meeting**  
**Chair:** Prof. John Prior (Switzerland), Dr. Savvas Frangos (Cyprus), Dr. Diana Páez (Austria) and Prof. Andrew Scott (Australia)
- 14:00 – 14:10** **Purpose of the meeting and WHA 78.13. Implications**  
 Prof. John Prior  
*WFNMB and Lausanne University Hospital (Switzerland)*
- 14:10 – 14:25** **Stakeholder Perspectives: Professional Organizations**  
 Prof. Elba Etchebehere  
*Brazilian Society of Nuclear Medicine and Molecular Imaging (Brazil)*
- Dr. Gopinath Gnanasegaran  
*Royal Free London Nhs Foundation Trust (United Kingdom)*
- 14:25 – 14:43** **Stakeholder Perspectives: Industry partners**  
 6 Panellists to be confirmed
- 14:43 – 14:49** **Stakeholder Perspectives: NGOs and academic institutions**  
 PhD. Efrain Perini  
*Oncidium Foundation (Belgium)*
- 14:49 – 15:10** **Stakeholder Perspectives: UN Organizations**  
 Dr. Diana Páez  
*International Atomic Energy Agency (Austria)*
- Prof. John Prior  
*WFNMB and Lausanne University Hospital (Switzerland)*
- 15:10 – 15:50** **Panel Discussion: Collaborative Pathways**  
**Moderators:** Dr. Savvas Frangos, Dr. Diana Páez, Dr. John Prior
- Panellist:** Representative from professional organizations, industry, NGOS, Academic institutions

**15:50 – 16:00** **Next Steps and Closing Remarks**

Prof. Andrew Scott

*Department of Molecular Imaging and Therapy,  
Austin Health (Australia)*

## Barahona Room 3+4

- 08:00 – 10:00 CME: Session: Theranostics in NETs**  
**Chair:** Dr. Partha Choudhury (India)
- 08:00 – 08:25 NET: summing up the past and ways in the future**  
 Prof. Irene Virgolini  
*Department of Nuclear Medicine, Medical University of Innsbruck (Austria)*
- 08:25 – 08:50 Management of challenging cases in Neuroendocrine Tumours**  
 Dr. Masha Maharaj  
*Umhlanga Molecular Imaging And Therapy: Centre of Excellence (South Africa)*
- 08:50 – 09:15 Genetics of Pheochromocytoma and Paraganglioma**  
 Dr. Roxana Chirico  
*Cemic (Argentina)*
- 09:15 – 09:40 Theranostics for Challenging Meningioma: Clinical Evidence, Practice, and Future Directions**  
 Prof. Sean Yan  
*University of Utah (United States)*
- 10:00 – 10:30 Morning Break** ☕
- 10:30 – 11:10 CME: Plenary Session: From Detection to Decision: How Next Generation Cancer Imaging will Drive Precision Oncology**  
**Chair:** Dr. Diana Páez (Austria)
- Prof. Michael S. Hofman  
*Peter MacCallum Cancer Centre (Australia)*
- 11:10 – 13:00 Closing Session**  
**Chair:** Dr. Diana Páez (Austria)
- 11:10 – 11:40 ALASBIMN, new image**  
 Dr. Camen Amelia De Los Reyes  
*ACMNIM, ALASBIMN and Inc (Colombia)*
- 11:40 – 12:00 Highlights**  
 Dr. Ramón Murgueitio  
*Clínica Shaio Foundation (Colombia)*

- 12:00 – 12:30 Award Ceremony**  
Dr. Víctor Marín  
*Fundacion Cardioinfantil-Lacardio (Colombia)*
- 12:30 – 13:00 Closing Remarks by the President of the Congress**  
Dr. Patricia Bernal Trujillo  
*WFNMB (Colombia)*

Barahona Room 3+4

## Barahona Room 1

- 08:00 – 10:00 Session: Theranostics and Humanistic Approaches**  
Chair: Dr. Mariela Agolti (Argentina)
- 08:00 – 08:25 Contribution of Therapeutic Nuclear Medicine on patients's quality of life**  
Dr. Ioannis Koutsikos  
*Henry Dunant Hospital Center (Greece)*
- 08:25 – 08:50 Coaching for healthcare workers**  
Dr. Claudia Guarnizo  
*ICF-International Coaching Federation (Colombia)*
- 08:50 – 09:15 The ICPO Foundation: Scaling Patient Access to Theranostics**  
Dr. Marwa Hakkam  
*ICPO Foundation (Germany)*
- 09:15 – 09:40 Increasing access to Radioligand therapy by the Oncidium foundation**  
PhD. Efrain Perini  
*Oncidium Foundation (Belgium)*

Barahona Room 1

## Barahona Room 2

- 08:00 – 09:30 Session: Pediatric Nuclear Medicine**  
Chairs: Dr. Alejandra Muñoz Meynet (Chile)  
and Dr. María Martínez (Colombia)
- 08:00 – 08:30 PETCT in benign diseases in childhood**  
Dr. Tatiana Morales  
*Atrys/SIMM (Spain)*
- 08:30 – 09:00 CZT SPECT-CT in pediatrics**  
Dr. Zvi Bar-Sever  
*Schneider Children's Hospital (Israel)*

Barahona Room 2

- 09:00 – 09:30** **Positron emission tomography in anti-NMDA receptor encephalitis**  
 Dr. Nora Kerik Rotenberg  
*Instituto Nacional de Neurología y Neurocirugía (Mexico)*

## Arsenal Room

- 08:00 – 10:00** **Oral Presentations 6: Oncology 2 and Endocrinology**  
 Chair: Dr. Eduardo Lischinsky (Uruguay)  
 and Dr. Mónica Vidal (Colombia)
- 08:00 – 08:07** **KANBAN: Implementation of Software for Patient Traceability in Radioiodine Treatments at the Arturo López Pérez Foundation**  
 Prof. Cristina Gutiérrez Correa  
*Fundación Arturo López Pérez (Chile)*
- 08:07 – 08:14** **Serum-stimulated thyroglobulin levels before radioactive iodine therapy as a predictive biomarker of disease-negative whole-body scan in differentiated thyroid cancer**  
 Dr. Andrés Gamboa  
*Unab (Colombia)*
- 08:14 – 08:21** **Positron emission tomography/computed tomography radiomics score predicts metabolically active disease and reflects glycolysis-related protein expression in aggressive B-cell lymphomas**  
 Mr. Farid Cury Neto  
*Barretos Cancer Hospital (Brasil)*
- 08:21 – 08:28** **Head-to-head inpatient qualitative comparison of 68Ga-FAPI-04 versus 18F-FDG PET/CT in various oncological pathologies**  
 Dr. Eduardo Lischinsky  
*CMNIM, Hospital de Clínicas "Dr. Manuel Quintela" Universidad de la República (Uruguay)*
- 08:28 – 08:35** **Comparison of 99mTc-MAA SPECT/CT and CECT with CBCT for Tumor Perfused Liver Volume Segmentation Prior to 90Y Radioembolization**  
 Dr. Leticia Portillo  
*INCMNSZ (Mexico)*

- 08:35 – 08:42 SPECTRA trial: Study of PD-L1 expression and molecular hybrid imaging in triple negative breast cancer: Response prediction and assesment**  
Dr. Sofía Denisse González Rueda  
*National Cancer Institute of Mexico (Mexico)*
- 08:42 – 08:49 Associated factors with positive [18F]FDG-PET/CT for distant metastasis in breast cancer**  
Dr. Ada Katerine Franco-Ardila  
*Universidad Autónoma De Bucaramanga Unab (Colombia)*
- 08:49 – 08:56 Development and Evaluation of a Novel Dual-Targeted <sup>68</sup>Ga-FAPI-TTP PET Probe for Enhanced Tumor Imaging**  
Mrs. Yi-fei Pei  
*Peking University Cancer Hospital & Institute, Department of Nuclear Medicine (China)*
- 08:56 – 09:03 Real-life applicability of Fluorocholine PET/CT in primary hyperparathyroidism**  
Dr. Mónica Vidal  
*Hospital Pablo Tobón Uribe (Colombia)*
- 09:03 – 09:10 Patient-specific factors in radioactive Iodine (I-131) clearance in Differentiated Thyroid Cancer (DTC) treatment**  
Dr. Ioannis Koutsikos  
*Henry Dunant Hospital Center (Greece)*
- 09:10 – 09:17 Bayesian survival modeling in multiple myeloma: prognostic PET/CT value with missing data imputation, preliminary results**  
Dr. Eliana Andrea González Artunduaga  
*Egresado Unal (Colombia)*
- 09:17 – 09:24 From Variability to Equity: An Eight-Year Retrospective Analysis of I-131 Therapeutic Practices in a Nuclear Medicine Service**  
Lic. Mariano Portillo  
*Instituto Alexander Fleming (Argentina)*

- 09:24 – 09:31** **Immunosuppressive molecular mechanisms potentially supporting development and progression of haematological malignancies triggered by abnormal or accidental exposure to nuclear irradiation**  
Dr. Vadim Sumbayev  
*University of Kent (United Kingdom)*
- 09:31 – 09:38** **SPECT-CT in Primary Hyperparathyroidism: the Intermediate Localization Method**  
Dr. Carlos Collaud  
*Hospital Italiano de Buenos Aires (Argentina)*
- 09:38 – 09:45** **Multiparametric Radiomic Analysis Based on <sup>18</sup>F-FDG PET, MRI and Biopsy for Predicting Pathological Complete Response to Breast Cancer Neoadjuvant Chemotherapy**  
Mr. Marco Guarín  
*Instituto Nacional de Cancerología (Colombia)*

# List of Oral Presentations

## **001 Diagnostic performance of 18F-choline PET/CT correlated with MRI in brain tumor recurrence: experience from an oncology hospital in Ecuador**

**Dr. Christian Toalongo Moreno**<sup>1,2</sup>, Dr. Abel Llaguno Buzetta<sup>1,2</sup>, Dr. Rodney Vaca Montenegro<sup>2</sup>

<sup>1</sup>SOLCA Oncology Hospital, Guayaquil, Ecuador, <sup>2</sup>Indoamérica Technological University, Quito, Ecuador

## **002 Diagnostic value of cisternoscintigraphy and CT cystenography in the detection of CSF leaks in patients with intracranial hypotension**

**Dr. Sebastián Rojas Lara**<sup>1</sup>

<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

## **003 Beyond clinical assessment: The value of combined metabolic and dopaminergic mapping with PET/CT for the differential diagnosis of parkinsonian syndromes**

**Dr. Abigail Arriaga Contreras**<sup>1</sup>, Dr. Rodrigo Hernández Ramírez<sup>1</sup>, Dr. Juan Pablo Chávez Torres<sup>1</sup>, Dr. Miguel Ángel Corza Ayala<sup>1</sup>, Dr. Francisco Jesús Solano Caballero<sup>1</sup>, Dr. Óscar Enrique Lucio Baez<sup>1</sup>, Dra. Blanca Estela López Graciano<sup>1</sup>

<sup>1</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico

## **004 Semiquantitative difference in the uptake of the pineal gland of [18F] fluorodopamine in patients with Parkinson's disease versus atypical parkinsonism**

**Dr. Kinari Ortega**<sup>1</sup>, Dr. Manlio Gerardo Gama<sup>1</sup>, Dr. Gustavo Vázquez<sup>1</sup>, Dr. Miguel Ángel Olarte Casas<sup>1</sup>

<sup>1</sup>National Autonomous University of Mexico, CDMX, Mexico

## **005 In vitro biological evaluation of a 99mTc tricarbonyl complex derived from Erlotinib for molecular imaging in triple negative breast cancer**

**Dr. María Emilia Tejería Pérez**<sup>1</sup>, Romina Rossi<sup>1</sup>, Ana María Rey Ríos<sup>1</sup>

<sup>1</sup>Área Radioquímica/Facultad de Química, Montevideo, Uruguay

## **006 Results from a First-In-Human Phase I Trial of [68Ga]Ga-OncoCAIX in ccRCC: Safety, Dosimetry, Pharmacokinetics and Preliminary Diagnostic Performance**

**Dr. Fabrizia Gelardi**<sup>1</sup>, Prof. Martina Sollini<sup>1,2</sup>, Dr. Cristiano Pini<sup>2</sup>, Rita Petrelli<sup>1</sup>, Alessia Tudda<sup>1</sup>, Prof. Paola Anna Erba<sup>3,4</sup>, Jacqueline Mock<sup>5</sup>, Samuele Cazzamalli<sup>5</sup>, Dario Neri<sup>5</sup>, Prof. Arturo Chiti<sup>1,2</sup>

<sup>1</sup>IRCCS San Raffaele Hospital, Milano, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milano, Italy, <sup>3</sup>School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy, <sup>4</sup>Nuclear Medicine Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>5</sup>Philochem AG, Otelfingen, Switzerland

### **O07 Ampelomins radiolabelled with Tc-99m and F-18: Synthesis and functionalization of tracers for imaging infectious processes**

Quim. Carolina Brindisi<sup>1,2</sup>, Dr. Javier Giglio<sup>2,3</sup>, **Dra. Mariella Adriana Terán Greter**<sup>2</sup>, Dra. Margarita Broveto<sup>1</sup>

<sup>1</sup>Química Orgánica (DQO) - Universidad de la República, Montevideo, Uruguay, <sup>2</sup>Área Área Radioquímica (DEC) - Universidad de la República, Montevideo, Uruguay, <sup>3</sup>Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay

### **O08 Radiosensitization of Theranostics for Pancreatic Ductal Adenocarcinoma**

**Dr. Moralba Domínguez García**<sup>1</sup>, Alexa Michel<sup>1</sup>, Mohamed Hussien<sup>1</sup>, Amy Morrison<sup>2</sup>, Dr. Jason S. Lewis<sup>1</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, United States, <sup>2</sup>King's College London, London, United Kingdom

### **O09 Validation of an Alternative Analytical Technique for Determining the Radiochemical Purity of <sup>99m</sup>Tc-HMDP**

**Mr. Eliecer Cantillo**<sup>1</sup>, Mr. Renzo Guardo<sup>1</sup>, Mr. Juan Balanta<sup>1</sup>, Ms. Viviana Montoya<sup>1</sup>, Mr. Giovanni Naranjo<sup>1</sup>

<sup>1</sup>Hospital Universitario Fundación Valle Del Lili, Cali, Colombia

### **O10 R1 from 18F-PR04.MZ as a proxy for cerebral blood flow in degenerative parkinsonisms: comparison with 15O-H2O PET/CT**

**Dr. Andrés Damian**<sup>1,2</sup>, Dr. Ignacio Amorin<sup>3</sup>, Dr. Vasko Kramer<sup>4</sup>, Dr. Juan R. Higgin<sup>3</sup>, TRI. Ismael Cordero<sup>1,2</sup>, Dr. Luis Gutiérrez<sup>2</sup>, Dr. Eduardo Savio<sup>1</sup>, Dra. Thalia Arias<sup>2</sup>, Dr. Omar Alonso<sup>1,2</sup>, Dr. Rodolfo Ferrando<sup>1,2</sup>

<sup>1</sup>Centro Uruguayo de Imagenología Molecular - Cudim, Montevideo, Uruguay, <sup>2</sup>Unidad Académica de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay, <sup>3</sup>Instituto de Neurología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay, <sup>4</sup>Nuclear Medicine and PET/CT Center PositronMed, PositronPharma SA., Santiago, Chile

### **O11 Evaluation of cortical amyloid burden and tau deposition in cognitively normal and preclinical Alzheimer's disease through positron emission tomography**

**Mr. Phelipi Nunes Schuck**<sup>1</sup>, Dr. Ana Maria Marques da Silva<sup>1,2</sup>

<sup>1</sup>Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, <sup>2</sup>Medical Imaging & Data Analytics (MEDIIMA), Porto Alegre, Brazil

### **O12 Influence of EEG Discharges During FDG-PET Cerebral Metabolism Assessment in Patients with Pharmacoresistant Epilepsy**

**Dr. Valentino Méndez**<sup>1</sup>, Dr. Andrés Damián<sup>1,2,3</sup>, Lic. María Pages<sup>3</sup>, Dra. Mariana Legnani<sup>3</sup>, Dr. Andrés Bertinat<sup>3</sup>, Dra. Patricia Braga<sup>3</sup>, Dr. Omar Alonso<sup>1,2</sup>, Dr. Rodolfo Ferrando<sup>1,2,3</sup>

<sup>1</sup>Unidad Académica de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay, <sup>2</sup>Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay, <sup>3</sup>Programa de Cirugía de Epilepsia del Hospital de Clínicas, Montevideo, Uruguay

### **O13 Evaluation of a murine model of metastatic castration resistant prostate cancer for combination radioligand therapy and immunotherapy**

**Dr. Cindy Rodríguez**<sup>1</sup>, Alexa Michel<sup>1</sup>, Moralba Domínguez García<sup>1</sup>, Angélique Loor<sup>1</sup>, Yana Reshetnyak<sup>2</sup>, Jason S. Lewis<sup>1</sup>

<sup>1</sup>Molecular Pharmacology Program Memorial Sloan Kettering Cancer Center, New York, United States, <sup>2</sup>Department of Physics University of Rhode Island, Kingston, United States

### **O14 Optimizing Pretargeted Radiotheranostics: From PET to Therapy**

**Mr. Mike Cornejo**<sup>1,2,3</sup>, Zachary V. Samuels<sup>1,2,3</sup>, Gina Dehlavi<sup>1,2,4</sup>, Lukas Carter<sup>5</sup>, Emilia Strugala<sup>1</sup>, Brian M. Zeglis<sup>1,2,4,6</sup>

<sup>1</sup>Department of Chemistry, Hunter College, The City University of New York, New York, United States, <sup>2</sup>Ph.D. Program in Chemistry, Graduate Center of the City of New York, New York, United States, <sup>3</sup>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, United States, <sup>4</sup>Ph.D. Program in Biochemistry, Graduate Center of the City University of New York, New York, United States, <sup>5</sup>Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, United States, <sup>6</sup>Department of Radiology, Weill Cornell Medical College, New York, United States

### **O15 Design and Astatination of Radioligands for the Pretargeted Delivery of Astatine-211**

**Mr. Mike Cornejo**<sup>1,2,3</sup>, Cindy Rodríguez<sup>2</sup>, Zachary Samuels<sup>1,2,3</sup>, Yutian Feng<sup>5</sup>, Michael R. Zalutsky<sup>5</sup>, Brian M. Zeglis<sup>1,2,3,4</sup>

<sup>1</sup>Department of Chemistry, Hunter College, The City University of New York, New York, United States, <sup>2</sup>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, United States, <sup>3</sup>Ph.D. Program in Chemistry, Graduate Center of the City University of New York, New York, United States, <sup>4</sup>Department of Radiology, Weill Cornell Medical College, New York, United States, <sup>5</sup>Department of Radiology, Duke University Medical Center, Durham, United States

### **O16 Combining deep learning and kinetic modeling for cerebral PET parametric imaging with reduced-time dynamic acquisitions**

**Lic. Santiago Burgos**<sup>1</sup>, Dr. Arturo Avendaño<sup>1,2</sup>, Dr. Miguel Ávila<sup>1,2</sup>

<sup>1</sup>Unidad Radiofarmacia-Ciclotrón, División de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad De México, México, <sup>2</sup>Centro de Investigación sobre el Envejecimiento, CINVESTAV Sede Sur, Ciudad de México, México

### **O17 High throughput scanning with a vertical and compact Walk-Through flat panel PET**

**Prof. Stefaan Vandenberghe**<sup>1</sup>, Dr. Jens Maebe<sup>1</sup>, Msc Maya Abi Akl<sup>1</sup>, Ir. Boris Vervenne<sup>1</sup>, Msc Rabia Aziz<sup>1</sup>, Ir. Thibault D'Hulster<sup>1</sup>, Ir. Florence Marie Muller<sup>1,3</sup>, Prof. Dr. Nadia Withofs<sup>2</sup>, Prof. Dr. Christian Vanhove<sup>1</sup>

<sup>1</sup>MEDISIP, Ghent University, Ghent, Belgium, <sup>2</sup>CHU Liege, Liege, Belgium, <sup>3</sup>PET instrumentation group, University Pennsylvania, Philadelphia, USA

### **O18 Internal Dosimetry Calculation for PET/CT with <sup>18</sup>F-PSMA-1007 Using OpenDose Software**

**Prof. Kelly Sandoval Sandoval**<sup>1</sup>, Prof. M. José Abarzua<sup>1</sup>, Prof. Jose Ceballos<sup>1</sup>

<sup>1</sup>Fundación Arturo López Perez, Santiago, Chile

### **O19 Quantitative Evaluation of Scatter Correction Strategies in Long Axial Field-of-View PET/CT**

**Dr. Mohammadreza Teimoorisichani**<sup>1</sup>, Dr. Inki Hong<sup>1</sup>

<sup>1</sup>Siemens Medical Solutions USA Inc., Knoxville, United States

### **O20 A Quantitative CT-less Reconstruction Workflow for Long-axial Field-of-view PET Scanners with Enhanced Scaling**

**Dr. Mohammadreza Teimoorisichani**<sup>1</sup>, Dr. Josh Schaefferkoetter<sup>1</sup>, Dr. Hasan Sari<sup>2,3</sup>

<sup>1</sup>Siemens Medical Solutions USA Inc., Knoxville, United States, <sup>2</sup>Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland, <sup>3</sup>Siemens Healthineers International AG, Zurich, Switzerland

### **O21 High-Precision PET/CT: Optimization and Quality strategies led by the Nuclear Medicine Technologist**

**Sra. Andrea Milena Bautista Beltran**<sup>1</sup>

<sup>1</sup>Clínica De Marly, Bogotá Dc, Colombia

### **O22 Brain MRI-guided PET Reconstruction in a New PET/MRI System with <200ps TOF resolution**

**Dr. Jorge Cabello**<sup>1</sup>, Dr. Karen Kettless<sup>2</sup>, Dr. Patrick Lehmann<sup>2,3</sup>, Dr. Anders Rodell<sup>2</sup>, Dr. Joshua Schaefferkoetter<sup>1</sup>, Dr. Ian Law<sup>4</sup>, Prof. Flemmin Littrup Andersen<sup>4,5</sup>, Dr. Thomas Lund Andersen<sup>4,5</sup>, Dr. Paul Schleyer<sup>1</sup>

<sup>1</sup>Siemens Medical Solutions USA, Knoxville, United States, <sup>2</sup>Siemens Healthcare A/S, Ballerup, Denmark, <sup>3</sup>Research & Clinical Translation, Magnetic Resonance, Siemens Healthineers AG, Erlangen, Germany, <sup>4</sup>Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark, <sup>5</sup>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

### **O23 Colombian Guide for the support of Radiological Events in Nuclear Medicine and Radiopharmacy**

**Mrs. Lorena Sandoval Castillo**<sup>1,2</sup>, Mrs. Eliana Franco<sup>1,3</sup>, Mrs. Ángela Londoño<sup>1,4</sup>, Mrs. Stephany Calderón<sup>1,5</sup>, Mrs. Erika Xiomara Cely<sup>1,6</sup>, Mrs. Patricia Rico<sup>1,7</sup>, Mrs. Nathalia Nuñez<sup>1,7</sup>, Mr. Harley J. Orjuela B.<sup>1,8</sup>, Mrs. Claudia Blanco<sup>1,9</sup>, Mr. Omar Patiño<sup>1,10</sup>

<sup>1</sup>Asociación Colombiana De Física Médica- ACOFIMED, Bogotá, Colombia, <sup>2</sup>Clínica del Country, Bogotá, Colombia, <sup>3</sup>Hospital Universitario Mayor Méderi, Bogotá, Colombia, <sup>4</sup>Medicina nuclear, Clínica de Occidente, Cali, Colombia, <sup>5</sup>Medicina Nuclear S.A., Valledupar, Colombia, <sup>6</sup>Servicio de medicina nuclear, Clínica Internacional de alta tecnología -Clinaltec, Ibagué, Colombia, <sup>7</sup>Grupo de Física Médica, Fundación Valle de Lili, Cali, Colombia, <sup>8</sup>Área de Física Médica, Hospital Serena del Mar, Cartagena de Indias, Colombia, <sup>9</sup>Servicio Geológico Colombiano, Bogotá, Colombia, <sup>10</sup>Física Médica Hospitalaria, Hospital Universitario de Caldas, Manizales, Colombia

#### **O24 Comparison of Patlak imaging with SUV imaging in metastatic uveal melanoma patients with a long axial field-of-view (LAFOV) PET/CT**

**Dr. Leyun Pan**<sup>1</sup>, Prof. Dr. Christos Sachpekidis<sup>1</sup>, Prof. Dr. Antonia Dimitrakopoulou-Strauss<sup>1</sup>

<sup>1</sup>German Cancer Research Center, Heidelberg, Germany

#### **O25 Clinical validation of deep learning denoising for low-count PET/CT: preserving SUV accuracy and image quality**

Dr. Mauro Namías<sup>1</sup>, **PhD Yamila Rotstein Habarnau**<sup>1</sup>, Dr. Nicolás Bustos<sup>1</sup>, Dr. Paola Corona<sup>1</sup>, Dr. Christian González<sup>1</sup>, Dr. Sonia Traverso<sup>1</sup>, Dr. Federico Matorra<sup>1</sup>, BSc Francisco Funes<sup>2</sup>, BSc Juan Martín Giraut<sup>1</sup>, PhD Laura Pelegrina<sup>2</sup>, Dr. Gabriel Bruno<sup>1</sup>

<sup>1</sup>Fundación Centro Diagnóstico Nuclear, Buenos Aires, Argentina, <sup>2</sup>Comisión Nacional de Energía Atómica, Buenos Aires, Argentina

#### **O26 Rapid scan assessment with non-quantitative FastPET: Generalizability to different tracers and count levels**

**Naveen Murthy**<sup>1</sup>, Dr. Yifan Zheng<sup>1</sup>, Dr. Vladimir Panin<sup>1</sup>, Dr. Deepak Bharkhada<sup>1</sup>, Dr. Paul Schleyer<sup>1</sup>

<sup>1</sup>Siemens Medical Solutions, USA, Inc., Knoxville, United States

#### **O27 Deep learning-based dose estimation for radionuclide therapy: a feasibility study**

**Dr. Yamila Rotstein Habarnau**<sup>1</sup>, Dr. Mauro Namías<sup>1</sup>

<sup>1</sup>Fundación Centro Diagnóstico Nuclear, Ciudad Autónoma de Buenos Aires, Argentina

#### **O28 Assessment of the impact of gastrointestinal motion on PET quantification due to mismatched CT**

**Dr. Giordana Salvi De Souza**<sup>1</sup>, Maria Giulia Toro<sup>1</sup>, Samaneh Mostafapour<sup>1</sup>, Johannes H. van Snick<sup>1</sup>, Adrienne H. Brouwers<sup>1</sup>, Charalampos Tsoumpas<sup>1</sup>

<sup>1</sup>Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

#### **O29 Optimization of pet/ct acquisition parameters for pregnant patients: phantom study with reduced dose and preserved image quality**

**Mr. Yann Cras**<sup>1</sup>, MD. Mariagiulia Longo<sup>1</sup>, MD. Camilo García<sup>1</sup>, Pr. Désirée Deandreis<sup>1</sup>, MD. Theophraste Henry<sup>1</sup>

<sup>1</sup>Gustave Roussy, Villejuif, France

#### **O30 Implementation of Innovative Toilet Filtration Systems for Radionuclide Therapy Effluents: First Latin American Clinical Experience**

MSc Eduardo Antonio González Villa<sup>1</sup>, MSc Cristhoper Camacho Herrera<sup>2</sup>, Dr. Dany Mena Cortes<sup>1,2</sup>, Bart Boots<sup>3</sup>, Mattijs Maris<sup>3</sup>, **Lic. Yesenia Saldierna Martinez**

<sup>1</sup>Oncología San José, Hermosillo, Mexico, <sup>2</sup>Nuclear Medicine World, Ciudad de Mexico, Mexico, <sup>3</sup>Zereau, Netherlands

**O31 Cocaine-dependent patients with depressive symptoms and suicide risk studied with brain perfusion SPECT and systemic inflammatory markers**

**Dr. Teresa Massardo**<sup>1</sup>, Dr. Juan Carlos Quintana<sup>2</sup>, Dr. Carlos Ibáñez<sup>1</sup>, Dr. Jonathan Veliz<sup>1</sup>, Dr. Rodrigo Jaimovich<sup>2</sup>, Dr. Claudia S Saez<sup>2</sup>, Dr. Jaime Pereira<sup>2</sup>, Dr. Francisco Javier Gómez<sup>1</sup>, Dr. Isabel Berrocal<sup>3</sup>, Dr. René Fernández<sup>1</sup>

<sup>1</sup>Hospital Clínico Universidad de Chile, Santiago, Chile, <sup>2</sup>Hospital Clínico Pontificia Universidad Católica de Chile, Santiago, Chile, <sup>3</sup>Hospital San Juan de Costa Rica, San Jose, Costa Rica

**O32 Radiosynoviorthesis with Erbium-169 Following Surgery for Ankle Pigmented villonodular synovitis: A Rare Disease Series with more than 5 Year Follow-Up**

**Prof. Ioannis Iakovou**<sup>1</sup>, MD Evanthia Giannoula<sup>1</sup>, MD Paraskevi Exadaktylou<sup>1</sup>, MD Efthalia Gatzouli<sup>1</sup>, MD Panos Charalambous<sup>1</sup>, MD Kyriaki Papadopoulou<sup>1</sup>, MD Agni Tsangaridi<sup>1</sup>, Prof. Argyrios Doumas<sup>1</sup>, Prof. Christos Sachpekidis<sup>2</sup>

<sup>1</sup>Aristotle University of Thessaloniki, Thessaloniki, Greece, <sup>2</sup>German Cancer Research Center, Heidelberg, Germany

**O33 Deep-learning-based positron range correction (PRC) for Rb-82 cardiac PET**

Dr. Yifan Zheng<sup>1</sup>, Nerea Encina-Baranda<sup>2</sup>, **Dr. Jorge Cabello**, Maurizio Conti<sup>1</sup>, Joaquín López Herraiz<sup>2</sup>

<sup>1</sup>Siemens Medical Solutions USA, Inc., Knoxville, United States, <sup>2</sup>Nuclear Physics Group and IPARCOS, University Complutense of Madrid (IdISSC), Madrid, Spain

**O34 Analysis of the Prognostic Value of Myocardial Perfusion Imaging – SPECT/CT Stratified by the AHA/ASCN 2021 Risk Algorithm**

**Dr. Sebastián Rojas Lara**<sup>1</sup>

<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

**O35 Towards a new classification of therapeutic response in IgG4-related disease: A cluster approach based on 18F-FDG PET/CT**

**Dr. Miguel Ángel Corza Ayala**<sup>1</sup>, Dr Rodrigo Hernández Ramírez<sup>1</sup>, Dr Joel Vargas Ahumada<sup>1</sup>, Dr Eduardo Martín Nares<sup>1</sup>, Dra Gabriela Aurora Hernández Molina<sup>1</sup>, Dr Juan Pablo Chávez Torres<sup>1</sup>

<sup>1</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

**O36 [99mTc]Tc-iFAP SPECT/CT as a new radiotracer for the evaluation of lesions in IgG4-related disease: Comparison with 18F-FDG PET/CT**

**Dr. Miguel Ángel Corza Ayala**<sup>1</sup>, Dr. Rodrigo Hernández Ramírez<sup>1</sup>, Dr. Joel Eduardo Vargas Ahumada<sup>1</sup>, Dr. Eduardo Marín Nares<sup>1</sup>, Dra. Gabriela Aurora Hernández<sup>1</sup>, Dr. Juan Pablo Chávez Torres<sup>1</sup>, Dra. Myrna Luna Gutiérrez<sup>2</sup>, Dr. Sevastián Salvador Medina Ornelas<sup>1</sup>, Dr. Daniel Carrillo Vázquez<sup>1</sup>, Dra. Abigail Arriaga Contreras<sup>1</sup>

<sup>1</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, <sup>2</sup>Instituto Nacional de Investigaciones Nucleares, Mexico City, Mexico City

**O37 Nitrate-enhanced technetium-99m-sestamibi single photon emission tomography for myocardial viability assessment: eleven-year single center experience**

**Dr. Eduardo Lischinsky**<sup>1</sup>, Dr. Mauricio Basantes<sup>1</sup>, Dr. Manuel Román<sup>1</sup>, Dr. Gerardo Dos Santos<sup>1</sup>, PhD MD Omar Alonso<sup>1</sup>

<sup>1</sup>CMNIM, Hospital de Clínicas "Dr. Manuel Quintela" – Universidad de la República, Montevideo, Uruguay

**O38 Myocardial perfusion patterns and ventricular function in patients with chagas disease, analysis at a regional reference center in eastern Colombia**

**Dr. Marvin Holman Anderson Achicanoy Botina**<sup>1</sup>, Ivan Camilo Ospina Florez<sup>1</sup>, Jose Fernando Silva Llanos<sup>1</sup>, César Augusto García Quintanilla<sup>1,2</sup>, Lizeth Catherine Rodríguez Corredor<sup>3</sup>

<sup>1</sup>Nuclear Medicine Postgraduate Program – Universidad Autónoma De Bucaramanga (UNAB), Bucaramanga, Colombia, <sup>2</sup>SPECT Medicina Nuclear S.A.S., Bucaramanga, Colombia, <sup>3</sup>Faculty of Health Sciences – Universidad Autónoma De Bucaramanga (UNAB), Bucaramanga, Colombia

**O39 Assessment of CCR2-Related Inflammatory Activity in Abdominal Aortic Aneurysms with 99mTc-HYNIC-CCR2-L and SPECT/CT**

**Dr. Jorge Rodríguez**<sup>1</sup>, Dr Javier Anaya Ayala, Dr Joel Eduardo Vargas Ahumada, Dr. Rodrigo Hernández Ramírez, Dr Felipe de Jesús Rodríguez Hernández

<sup>1</sup>Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico

**O40 SPECT/CT with [99mTc]Tc-UBI 29-41 in challenging-to-diagnose infections: clinical concordance and impact on redefining the initial diagnosis**

**Dr. Hernando Andrés Benavides Jiménez**<sup>1</sup>, Dr. Luz Kelly Anzola Fuentes<sup>3</sup>, Dr. Viviana Andrea Daza Betancourt<sup>1</sup>, Dr. Cristian Camilo Vargas López<sup>1</sup>, Dr. Sebastián Rojas Lara<sup>1</sup>, Dr Sergio Moreno López<sup>4</sup>, Dr Carlos Alvarez Moreno<sup>2</sup>

<sup>1</sup>Fundación Universitaria Sanitas, Bogota, Colombia, <sup>2</sup>Clinica Reina Sofia, Bogota, Colombia, <sup>3</sup>Clinica Universitaria Colombia, Bogota, Colombia, <sup>4</sup>Universidad Nacional de Colombia, Bogota, Colombia

**O41 Splenic uptake in dipyridamole stress and rest tc-99m mibi spect: a potential vasodilatory marker**

**Dr. Paula Aristov**<sup>1</sup>, Dr. Andrés Damián<sup>1</sup>, Dr. Rodolfo Ferrando<sup>1</sup>, Dr. Omar Alonso<sup>1</sup>, Dr. Federico Ferrando<sup>1</sup>, Técnico Aldo Sánchez<sup>1</sup>, Técnico Pablo Bracesco<sup>1</sup>

<sup>1</sup>Servicio Medicina Nuclear, Hospital De Clinicas, Montevideo, Uruguay

**O42 Cannabidiol prevents age-related cognitive decline and neuroinflammation, and enhances brain metabolism in a Down syndrome animal model**

**Dr. Lidia Spelta**<sup>1</sup>, Chiara Righini<sup>1</sup>, Jean Brizola<sup>1</sup>, Dr. Carlos Buchpiguel<sup>1</sup>, Dr. José Alexandre Crippa<sup>2</sup>, Dr. Daniele de Paula Faria<sup>1</sup>

<sup>1</sup>Laboratory of Nuclear Medicina, Faculty of Medicine, University of São Paulo (USP), São Paulo, Brazil, <sup>2</sup>Department of Neurosciences and Behavior, Faculty of Medicine from Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, Brazil

#### **O43 Quantitative 99mTc-PYP SPECT/CT in ATTR-CA: head-to-head MBR, LV/bone and SUVmax with near-perfect discrimination**

**Mr. Luciano Santos**<sup>1</sup>, Mrs. Agustina Pérez<sup>1,2</sup>, Mr. Pablo Roman<sup>1,2</sup>, Mrs. Karina Bayardo<sup>2</sup>, Mr. Federico Ferrando<sup>1,2</sup>, Mr. Rodolfo Ferrando<sup>1,2</sup>

<sup>1</sup>Consultorio De Medicina Nuclear Ffp., Montevideo, Uruguay, <sup>2</sup>Centro de Medicina Nuclear e Imagenología Molecular del Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay., Montevideo, Uruguay

#### **O44 Myocardial perfusion imaging: When is not just supine, not just prone**

**Dr. Romina Lorena Romero**<sup>1</sup>, Dr. Karina Quintero<sup>2</sup>, Dr. María del Carmen Alak<sup>1</sup>, Dr. César Mendez<sup>1</sup>, Lic. Hernan Policella<sup>1</sup>, Lic. Antonio Casares<sup>1</sup>, Lic. Macarena Montaña<sup>1</sup>

<sup>1</sup>Hospital Británico De Buenos Aires, Buenos Aires, Argentina, <sup>2</sup>Hospital de Pediatría Dr. Juan P. Garrahan, Buenos Aires, Argentina

#### **O45 Standardized Formulation of a Business Case for a PET-CT Nuclear Medicine Service in Colombia**

**Dr. Saule Karanauskas**<sup>1</sup>, Ingeniera Lenys Roncancio<sup>1</sup>, Dr. María Martínez<sup>1</sup>

<sup>1</sup>Medicina Nuclear Diagnostica, Villavicencio, Colombia

#### **O46 [177Lu]Lu-DOTA-ATWLPPR/(D-Lys6-LHRH) peptide heterodimer as a potential theragnostic agent for prostate and breast cancer**

**Dr. Ximena Camacho**<sup>1</sup>, MSc. Carolina Perroni<sup>1</sup>, Dr. Mirel Cabrera<sup>1</sup>, Dr. Lucía Alfaya<sup>1</sup>, Dr. Marcos Tassano<sup>1</sup>, MSc. Ana Laura Reyes<sup>2</sup>, Tech. Andrea Paolino<sup>2</sup>, Dr. Eduardo Savio<sup>2</sup>, Dr. Juan Pablo Gambini<sup>1,2</sup>, Dr. Pablo Cabral<sup>1</sup>

<sup>1</sup>Universidad de la República, Montevideo, Uruguay, <sup>2</sup>Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay

#### **O47 Targeted ROR1 protein degradation combined with PET imaging reveals the role of ROR1 in overcomes EGFR Resistance in NSCLC**

**Mr. Bo Mei**<sup>1</sup>, Prof Zhi Yang<sup>1</sup>, Prof Lei Xia<sup>1</sup>

<sup>1</sup>Peking University Cancer Hosiptal, Beijing, China

#### **O48 Preclinical evaluation of <sup>212</sup>Pb-labeled CXCR4 peptides for targeted alpha therapy in colorectal carcinomatosis**

**Mr. Richard Whiteside**<sup>1</sup>, Nasrin Abbasi-Gharibkandi<sup>1</sup>, Fabio Gallazzi<sup>1</sup>, Jessica Newton-Northup<sup>1</sup>, Meltem Ocak<sup>1</sup>, David Bauer<sup>1</sup>

<sup>1</sup>The University of Missouri, Columbia, United States

#### **O49 Intraoperative Sentinel Lymph Node Mapping with Dual Modality (Radioisotopic/Optical) Using 99mTc-ICG Nanocolloid: Improved Precision and Overcoming Clinical Limitations**

**Mrs. Carolina Furtado Prieto**<sup>1,2</sup>, Ms. Bettina Martinucci<sup>1</sup>, Ms. Mirel Cabrera<sup>2</sup>, Ms. Ximena Camacho<sup>2</sup>, Mr. Marcos Tassano<sup>2</sup>, Mr. Omar Alonso<sup>1</sup>, Mr. Gustavo Burroso<sup>3</sup>, Mr. Pablo Duarte<sup>3</sup>, Mr. Alarico Rodríguez<sup>3</sup>, Mr. Pablo Cabral<sup>2</sup>, Mr. Juan Pablo Gambini<sup>1,3</sup>

<sup>1</sup>UA Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, UdelaR, Montevideo, Uruguay, <sup>2</sup>Centro de Investigaciones Nucleares, Facultad de Ciencias, UdelaR, Montevideo, Uruguay, <sup>3</sup>Centro Uruguayo de Imegenología Molecular, Montevideo, Uruguay

### **O50 Intraoperative near-infrared lymphatic mapping in thyroid cancer using intrathyroidal indocyanine green**

**Mrs. Carolina Furtado Prieto**<sup>1,2</sup>, Ms Bettina Martinucci<sup>1</sup>, Ms Carolina Guarneri<sup>3</sup>, Mr Ulises Parada<sup>3</sup>, Mr Pablo Duarte<sup>4</sup>, Mr Omar Alonso<sup>1</sup>, Mr Gustavo Burroso<sup>4</sup>, Mr Alarico Rodríguez<sup>4</sup>, Mr Pablo Cabral<sup>2</sup>, Mr Juan Pablo Gambini<sup>1,4</sup>

<sup>1</sup>UA Medicina Nuclear e Imagenología Molecular, Centro de Investigaciones Nucleares - Universidad de la República, Montevideo, Uruguay, <sup>2</sup>Centro de Investigaciones Nucleares, Facultad de Ciencias, UdelaR, Montevideo, Uruguay, <sup>3</sup>Unidad Académica Clínica Quirúrgica A, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, UdelaR, Montevideo, Uruguay, <sup>4</sup>Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay

### **O51 Diagnostic Accuracy of Robotic Arm assisted Real time PET-CT guided Biopsy of Abdomino-pelvic lesions including Retroperitoneal lesions**

**Dr. Arun Ravi John**<sup>1</sup>, Dr Jeenu Varghese<sup>1</sup>, Dr Srivallabh Dande<sup>1</sup>, Dr TVSVGK Tilak<sup>1</sup>

<sup>1</sup>Command Hospital Air Force, Bengaluru, India

### **O52 Bridging Vision and Practice: The Journey to Implementing a Theranostics Centre at the University Health Network in Toronto, Canada**

**Dr. Luke Brzozowski**<sup>1</sup>

<sup>1</sup>University Health Network, Toronto, Canada

### **O53 Real-world efficacy: first prospective study in Argentina of the effectiveness and safety of 177Lu-DOTATATE in GEP-NET**

Dr. Silvina Racioppi<sup>1</sup>, Dr. Eduardo Cardozo<sup>2</sup>, Lic. Mariano Portillo<sup>1</sup>, **Lic. Mariano Portillo**<sup>1</sup>, Dr. Martina Musumeci<sup>1</sup>, Lic. Marcos Mussio<sup>1</sup>, Dr. Federico Estesio<sup>2</sup>, Dr. Juan Manuel OConnor<sup>2</sup>

<sup>1</sup>Servicio de Medicina Nuclear, Instituto Alexander Fleming, Buenos Aires, Argentina,

<sup>2</sup>Servicio de Oncología Clínica, Instituto Alexander Fleming, Buenos Aires, Argentina

### **O54 Intraoperative metabolic assessment (PET-CT) of surgical margins in breast cancer: a novel challenge in oncologic surgery**

**Dr. John Orozco Cortés**<sup>1</sup>, Dr. Jorge Sabater Sancho<sup>2</sup>, Dr. Elvira Buch Villa<sup>3</sup>, Dr. Ernesto Muñoz Sornosa<sup>3</sup>, Dr. Vicente López Flor<sup>3</sup>, Dr. Tomas Mut Dolera<sup>3</sup>, Dr. LÍliria Terradezas<sup>3</sup>, Dr. Octavio Burgués Gaisón Burgués Gaisón<sup>3</sup>, Dr. MMarcos AdrianzenVargas<sup>3</sup>, Dr. RafRafael Díazpósito<sup>4</sup>

<sup>1</sup>Hospital Universitario Dr. Peset, Valencia, Spain, <sup>2</sup>Consortio Hospitalario Provincial de Castellón, Castellon, Spain, <sup>3</sup>Hospital Clínico Universitario de Valencia, Valencian, Spain, <sup>4</sup>Hospital Universitario y Politecnico la Fe, Valencia, Spain

### **O55 Freehand-SPECT augmented reality navigation compared with planar scintigraphy for sentinel lymph node biopsy in breast cancer**

**Dr. John Orozco Cortés**<sup>1</sup>, Dr. Franco Jose Cavagna Matti<sup>1</sup>, Dr. Ángela Esteban Hurtado<sup>2</sup>, Dr Georgina Bonino<sup>1</sup>, Dr PPedro AbreuSánchez<sup>1</sup>, Dr. Jose Rafael Infante de la Torre<sup>1</sup>, Dr Fabrizio Montenegro Muñoz<sup>1</sup>, Dr. Laura Casas Calabuig<sup>1</sup>, Dr. Maria Dolores Reyes Ojeda<sup>1</sup>, Dr Elisa Veronica Caballero Calabuig<sup>1</sup>

<sup>1</sup>Hospital Universitario Dr. Peset, Valencia, Spain, <sup>2</sup>Centre Medic Alomar, Barcelona, Spain

### **O56 First experience with molecular surgery in pancreatic and hepatic cancer using PET radiopharmaceuticals**

**Dr. John Orozco Cortés**<sup>1</sup>, Dr. Jorge Sabater Sancho<sup>2</sup>, Dr. Luis Sabater Ortí<sup>3</sup>, Dr. Antonio Stacey Solis<sup>3</sup>, Dr. Elena Muñoz Forner<sup>3</sup>, Dr. Maria del Puig Cozar Santiago<sup>3</sup>, Dr. Marina Garces Albir<sup>3</sup>, Dr. Carolina Castillorrias<sup>3</sup>, Dr. Maria Carmen Redal Peña<sup>3</sup>, Dr. Rafael Díaz Expósito<sup>4</sup>

<sup>1</sup>Hospital Universitario Dr. Peset, Valencia, Spain, <sup>2</sup>Consortio Hospital Provincial de Castellon, Castellon, Spain, <sup>3</sup>Hospital Clinico Universitario de Valencia, Valencia, Spain, <sup>4</sup>Hospital Universitario y Politecnico la Fe, Valencia, Spain

### **O57 Impact of fixed SUV thresholds on lesion segmentation in psma pet/ct: methodological implications for recip response assessment to lu177-psma-617 therapy**

**Mr. Yann Cras**<sup>1</sup>, MD. Khalil Trabelsi<sup>1</sup>, MD. Adam Bekkhoucha<sup>1</sup>, MD. Tarek Kamoun<sup>1</sup>, MD. Mehdi Borsali<sup>1</sup>, Pr. Désirée Deandreis<sup>1</sup>, DR. Camilo García<sup>1</sup>

<sup>1</sup>Gustave Roussy, Villejuif, France

### **O58 Limitations of applying the hänscheid single-time-point method to 177Lu-psma-617 organ dosimetry: toward psma-specific simplified protocols**

**Mr. Yann Cras**<sup>1</sup>, MD. Khalil Trabelsi<sup>1</sup>, MD. Adam Bekkhoucha<sup>1</sup>, MD. Tarek Kamoun<sup>1</sup>, MD. Mehdi Borsali<sup>1</sup>, Pr. Désirée Deandreis<sup>1</sup>, MD. Camilo García<sup>1</sup>

<sup>1</sup>Gustave Roussy, Villejuif, France

### **O59 Selection of Patients for Lutetium-177 DOTATATE Therapy Using Tc-99m HYNIC-TOC Scintigraphy: Preliminary Experience in a Peruvian Center**

**Dr. Shirley Alarcon**<sup>1</sup>, Dr. Estuardo Paredes

<sup>1</sup>Clinica Ricardo Palma, Lima, Perú

### **O60 Biochemical Variability in the Response to [177Lu]Lu-iPSMA in Heavily Pretreated Patients: Real-World Experience**

**Dr. Edgar Hernández**<sup>1</sup>, Dr. Francisco Osvaldo García Pérez<sup>1</sup>, Dra. Irma Soldevilla Gallardo<sup>2</sup>, Dra. Quetzali Gabriela Pitalua Cortés<sup>3</sup>, Dra. Sofía Denisse González Rueda<sup>1</sup>

<sup>1</sup>INCan, Cdmx, México, <sup>2</sup>ABC, CDMX, México, <sup>3</sup>Medica Sur, CDMX, México

### **O61 Role of 18F-PSMA-(Pylclari) and 68Ga-PSMA-11 PET-CT in the staging of high-risk prostate cancer**

Javier Jesus Robles Barba<sup>1</sup>, Juan José Martín Marcuartu<sup>1</sup>, **Dr. Carlos Andrés Tapias Mesa**<sup>1</sup>, Jorge Luis Díaz Moreno<sup>1</sup>, Andrea Bagan Trejo<sup>1</sup>, Marta Zamorano Rivas<sup>1</sup>, David Durany Lara<sup>2</sup>, María Pane Foix<sup>3</sup>, Jose Francisco Suarez Novo<sup>4</sup>, Montserrat Cortes Romera<sup>1</sup>

<sup>1</sup>Servicio de Medicina Nuclear / PET (IDI). Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain, <sup>2</sup>Servicio de Radiología. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain, <sup>3</sup>Servicio de Anatomía Patológica. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain, <sup>4</sup>Servicio de Urología. Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Spain

### **O62 <sup>99m</sup>Tc-HYNIC-iPSMA SPECT/CT in Prostate Cancer: A Real-World Data Multicentric Study in 457 Mexican Patients**

**Dr. Joel Vargas Ahumada**<sup>1</sup>, Dr. Luis Vargas Rodríguez<sup>1</sup>, Dr. Sergio López Buenrostro<sup>2</sup>, Dr. Paola Vallejo Armenta<sup>1</sup>, Dr. Ana L. Calderón Ávila<sup>3</sup>, Dr. Eleazar Ignacio Álvarez<sup>4</sup>, Dr. Fabio A. Sinisterra Solis<sup>1</sup>

<sup>1</sup>Imagenología Diagnóstica, Xalapa, México, <sup>2</sup>Unidad de Patología Clínica, Guadalajara, México, <sup>3</sup>Centro Médico Nacional Siglo XXI, Ciudad de México, México, <sup>4</sup>Hospital Almater, Mexicali, México

### **O63 Prospective head-to-head comparison of <sup>18</sup>F-PSMA -1007 and <sup>18</sup>F-DCFPyl PET/CT for primary skeletal staging in high-risk prostate cancer**

**Dr. Marko Seppänen**<sup>1</sup>, Simona Malaspina<sup>1</sup>, Ekaterina Saukko<sup>2</sup>, Tommi Noponen<sup>3</sup>, Jukka Kemppainen<sup>1</sup>, Mikael Anttinen<sup>4</sup>, Suvi Hartikainen<sup>5</sup>, Janne Salonen<sup>6</sup>, Peter Boström<sup>4</sup>, Otto Ettala<sup>4</sup>

<sup>1</sup>Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland, <sup>2</sup>Department of Radiology, Turku University Hospital and University of Turku, Turku, Finland, <sup>3</sup>Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital, Turku, Finland, <sup>4</sup>Department of Urology, University of Turku and Turku University Hospital, Turku, Finland, <sup>5</sup>Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland, <sup>6</sup>Department of Nuclear Medicine, University of Helsinki and Helsinki University hospital, Helsinki, Finland

### **O64 Validation of PET/CT with <sup>18</sup>F-NOTA-Oc and <sup>18</sup>F-FDG for obtaining the “NETPET score” as a prognostic biomarker in neuroendocrine neoplasms**

**Dr. Francisco Jesus Solano Caballero**<sup>1</sup>, Dr. Rodrigo Hernández Ramírez<sup>1</sup>, Dr. Juan Pablo Chávez Torres<sup>1</sup>, Dra. Natalia Ramírez Pedraza<sup>1</sup>, Dra. Ailan Hitandhui Barrientos Priego<sup>1</sup>, Dr. Miguel Angel Corza Ayala<sup>1</sup>, Dra. Abigail Arriaga Contreras<sup>1</sup>

<sup>1</sup>Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Tlalpan, Mexico

### **O65 [<sup>99m</sup>Tc]Tc-HYNIC-PEG4-ATWLPPR/Tricine peptide as a potential diagnostic agent for prostate cancer: In vitro evaluation**

**Mrs. Carolina Perroni Zanoniani**<sup>1</sup>, Dr Ximena Camacho<sup>1</sup>, Dr Mirel Cabrera<sup>1</sup>, Dr Lucía Alfaya<sup>1</sup>, Dr Marcos Tassano<sup>1</sup>, Dr Juan Pablo Gambini<sup>3</sup>, Dr Pablo Cabral<sup>1</sup>

<sup>1</sup>Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay, <sup>2</sup>Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay, <sup>3</sup>Centro de Medicina Nuclear e Imagenología Molecular Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay

### **O66 Results from a Prospective Phase I Clinical Trial on [68Ga]Ga-OncoACP3 in Prostate Cancer: Safety, Dosimetry, Pharmacokinetics and Diagnostic Performance**

**Dr. Cristiano Pini**<sup>1</sup>, Dr. Fabrizia Gelardi<sup>1</sup>, Prof. Martina Sollini<sup>1,2</sup>, Dr. Anna Piai<sup>3</sup>, Dr. Rita Petrelli<sup>2</sup>, Prof. Paola Anna Erba<sup>4,5</sup>, Dr. Jacqueline Mock<sup>6</sup>, Dr. Samuele Cazzamalli<sup>6</sup>, Dr. Dario Neri<sup>6</sup>, Prof. Arturo Chiti<sup>1,2</sup>

<sup>1</sup>Vita-salute San Raffaele University, Milan, Italy, <sup>2</sup>Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, Italy, <sup>3</sup>Medical Physics Department, IRCCS Ospedale San Raffaele, Milan, Italy, <sup>4</sup>School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy, <sup>5</sup>Nuclear Medicine Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>6</sup>Philochem AG, Otelfingen, Switzerland

### **O67 Prostate Tumor Volume by 68Ga-PSMA PET/CT as a Predictor of Lymph Node Metastases in High-Risk Prostate Cancer**

**Dr. Angie Paola Llanos Cuellar**<sup>1</sup>, Ana Milena Gualdrón-Naranjo<sup>1</sup>, Liliana Patricia Torres-Agredo<sup>2</sup>, Humberto Varela-Ramírez<sup>2</sup>, Alejandra Gómez-Marting<sup>1</sup>, Helen Johanna Mejía-Efeer<sup>1</sup>, Milton Yesid Gómez-Buitrago<sup>1</sup>, Marco Antonio Parra-Pérez<sup>1</sup>  
<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, Colombia, <sup>2</sup>Instituto Nacional de Cancerología, Bogotá, Colombia

### **O68 Usefulness of Fluoride PET CT 18F-Alf Nota on suspicion of well-differentiated neuroendocrine tumors (NETs)**

**Dr. Francisco Gómez**<sup>1</sup>, Dr. Alejandro Rojas<sup>1</sup>, Dr. Juan Dupouy<sup>1</sup>, Dr. Teresa Massardo<sup>1</sup>, Dr. José Tomás Donoso<sup>1</sup>, Dr. Paloma Peña<sup>1</sup>, Dr. Evelyn Ortiz<sup>1</sup>, Dr. Francisco Tortorolo<sup>1</sup>, Dr. Rocío Hidalgo<sup>1</sup>, Ms. Sofía Rivas<sup>1</sup>  
<sup>1</sup>Hospital Clínico Universidad De Chile, Santiago, Chile

### **O69 [18F]SiTATE in neuroendocrine neoplasia (NEN): first Latin America experience in prostate, lung and colon NEN patients**

**Dr. Emiliano Michel Sánchez**<sup>1</sup>, Dr. Vikas Prasad<sup>2</sup>, MSc Eduardo Antonio González Villa<sup>1</sup>, BSc. Francisco Rafael Peres Anaya<sup>1</sup>, Dr. Danny Roberto Mena Cortes<sup>1</sup>  
<sup>1</sup>Oncología San Jose, HERMOSILLO, Mexico, <sup>2</sup>Mallinckrodt Institute of Radiology, St. Louis, US

### **O70 Clinical Impact Of 18F-PSMA-1007 PET/CT In the Evaluation of Prostate Cancer Patients: Analysis Of 511 Patients in Different Clinical Scenarios**

**Dr. Gerardo Dos Santos**<sup>1,2</sup>, Dra. Agustina Banchemo<sup>1</sup>, Dra. Marta Iraetha<sup>1</sup>, Dr. Mauriel Díaz<sup>1</sup>, Dr. César Ferreira<sup>2</sup>, Dr. Eduardo Lischinky<sup>2</sup>, Technician Ismael Cordero<sup>1</sup>, Dr. Omar Alonso<sup>1,2</sup>  
<sup>1</sup>Uruguayan Center of Molecular Imaging (CUDIM), Montevideo, Uruguay, <sup>2</sup>Nuclear Medicine and Molecular Imaging Center, Clinical Hospital "Dr. Manuel Quintela" University of Uruguay, Montevideo, Uruguay

### **071 Magnitude of change in radiotherapy planning in biochemical recurrence of prostate cancer. From theoretical planned to definitive treatment post-PET-TC PSMA**

**Dr. Pedro Jose Plaza López**<sup>1,2</sup>, Dr Francesco Amorelli<sup>3</sup>, Dr Juan Sebastián Blanco<sup>1</sup>, Dra. Eliana Carrillo<sup>1</sup>, Dra. Natali Augusto<sup>4</sup>, Dra. Palmira Foro<sup>2,3</sup>

<sup>1</sup>Hospital del Mar. Nuclear Medicine Department, Barcelona, Spain, <sup>2</sup>Universitat Pompeu Fabra, Barcelona, España, <sup>3</sup>Hospital del Mar. Radiation Oncology Department, Barcelona, España, <sup>4</sup>Hospital Josep Trueta. Clinical Analysis Department, Girona, España

### **072 Biochemical Response Following PSMA-1007 Metabolic Imaging-Guided Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy**

**Dr. Pedro Jose Plaza López**<sup>1,2</sup>, Dr. Francesco Amorelli<sup>3</sup>, Dr. Juan Sebastián Blanco<sup>1</sup>, Dra. Raquel Valhondo<sup>1</sup>, Dra Cristina Soldevilla<sup>1</sup>, Dra Patricia Stefanelli<sup>1</sup>, Dra Palmira Foro<sup>2,3</sup>

<sup>1</sup>Hospital del Mar. Nuclear Medicine Department, Barcelona, Spain, <sup>2</sup>Universitat Pompeu Fabra, Barcelona, España, <sup>3</sup>Hospital del Mar. Radiation Oncology Department, Barcelona, España

### **073 Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET-CT in prostate cancer patients with occult biochemical recurrence with low PSA values**

**Dr. Pedro Jose Plaza López**<sup>1</sup>, Dr. Francesco Amorelli<sup>3</sup>, Dr. Juan Sebastián Blanco<sup>1</sup>, Dra. Eliana Carrillo<sup>1</sup>, Dra. Raquel Valhondo<sup>1</sup>, Sr. Guillermo García Álvaro<sup>1</sup>, Dra. Palmira Foro<sup>2,3</sup>

<sup>1</sup>Hospital del Mar. Nuclear Medicine Department, Barcelona, Spain, <sup>2</sup>Universitat Pompeu Fabra, Barcelona, España, <sup>3</sup>Hospital del Mar. Radiation Oncology Department, Barcelona, España

### **074 Non-informative [18F]FDG PET/CT studies and rescheduling times as quality indicators in a Latin American reference center**

**Mr. Ismael Cordero**<sup>1</sup>, Mr. Martin Sabatella<sup>1</sup>, Mr. Javier Giglio<sup>1</sup>, Mr. Omar Alonso<sup>1</sup>, Mr. Gustavo Burroso<sup>1</sup>, Mr. Juan Pablo Gambini<sup>1</sup>

<sup>1</sup>Uruguayan Center of Molecular Imaging (CUDIM), Montevideo, Uruguay

### **075 Synergy in sight: fusing PSMA PET/CT and mpMRI parameters to enhance prostate cancer risk stratification**

**Dr. Eva Lorena Valadez Montero**<sup>1</sup>, Dr. Bethsabel Rodríguez Encinas, MD. Irma Soldevilla Gallardo

<sup>1</sup>CENTRO MEDICO ABC, Mexico City, Mexico

### **076 KANBAN: Implementation of Software for Patient Traceability in Radioiodine Treatments at the Arturo López Pérez Foundation**

**Prof. Cristina Gutiérrez Correa**<sup>1</sup>, Prof. Dennys Cuevas Gómez<sup>1</sup>, Prof. Fernando Navarro<sup>1</sup>, Prof. Sergio Veliz<sup>1</sup>, Prof. Ruben Olave<sup>1</sup>, Prof. Miguel Rojas<sup>1</sup>, Prof. Luis Madariaga<sup>1</sup>, Dra. M. Josefina Jofre<sup>1</sup>

<sup>1</sup>Fundación Arturo López Pérez, Santiago, Chile

### **077 Serum-stimulated thyroglobulin levels before radioactive iodine therapy as a predictive biomarker of disease-negative whole-body scan in differentiated thyroid cancer**

**Dr. Andrés Gamboa**<sup>1</sup>, Dr. Liset Sánchez<sup>1,2</sup>, Dr. Mabel Gómez<sup>1</sup>, Dr. Wendy Gallegos<sup>1</sup>, Dr. César García<sup>1,2</sup>, Dr. Tatiana Morales<sup>1</sup>, Dr. Lizeth Rodríguez<sup>1</sup>

<sup>1</sup>Universidad Autónoma de Bucaramanga - UNAB, Bucaramanga, Colombia, <sup>2</sup>SPECT S.A.S, Bucaramanga, Colombia

### **078 Positron emission tomography/computed tomography radiomics score predicts metabolically active disease and reflects glycolysis-related protein expression in aggressive B-cell lymphomas**

**Mr. Farid Cury Neto**<sup>1,2</sup>, Mr. Gabriel de Prince García<sup>2</sup>, MSc. Patrik da Silva Vital<sup>1</sup>, Dr. Murilo Bonatelli<sup>1</sup>, Mr. José Augusto Santanna Otteiro<sup>3</sup>, MD., MSc. Flávia Fazzo Barbin<sup>4</sup>, MD., MSc. Eduardo Caetano Albino da Silva<sup>4</sup>, Dr. Marcelo Wilson Berbone Furlan Alves<sup>5</sup>, MD., Dr. Wilson Eduardo Furlan Matos Alves<sup>2,3</sup>, Dr. Céline Pinheiro<sup>1,2</sup>

<sup>1</sup>Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil, <sup>2</sup>Barretos School of Health Sciences Dr. Paulo Prata, Barretos, Brazil, <sup>3</sup>Department of Nuclear Medicine, Barretos Cancer Hospital, Barretos, Brazil, <sup>4</sup>Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil, <sup>5</sup>Aeronautical Technology Institute, São José dos Campos, Brazil

### **079 Head-to-head inpatient qualitative comparison of 68Ga-FAPI-04 versus 18F-FDG PET/CT in various oncological pathologies**

**Dr. Eduardo Lischinsky**<sup>1</sup>, Javier Giglio<sup>2</sup>, Eduardo Savio<sup>2</sup>, Ismael Cordero<sup>1,2</sup>, Dr. Omar Alonso<sup>1,2</sup>, Dr. Gustavo Burroso<sup>2</sup>, Dr. Alarico Rodríguez<sup>2</sup>, Dr. Juan Pablo Gambini<sup>1,2</sup>

<sup>1</sup>CMNIM, Hospital De Clínicas "Dr. Manuel Quintela" - Universidad De La República, Montevideo, Uruguay, <sup>2</sup>Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay

### **080 Comparison of 99mTc-MAA SPECT/CT and CECT with CBCT for Tumor Perfused Liver Volume Segmentation Prior to 90Y Radioembolization**

**Dr. Leticia Portillo**<sup>1</sup>, Dr. Rodrigo Hernández Ramírez<sup>1</sup>, Dr. Miguel Ángel Corza Ayala<sup>1</sup>, Dr. Juan Pablo Chávez Torres<sup>1</sup>

<sup>1</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico

### **081 SPECTRA trial: Study of PD-L1 expression and molecular hybrid imaging in triple negative breast cancer: Response prediction and assesment**

**Dr. Sofía Denisse González Rueda**<sup>1,2</sup>, Dr. José Antonio García Gordillo<sup>1</sup>, Dr. Carlos Arturo González Núñez<sup>1</sup>, Dr. Sergio Israel Aguilar Villanueva<sup>1</sup>, Dr. Francisco Osvaldo García Pérez<sup>1</sup>, Dr. Juan Enrique Bargalló Rocha<sup>1,4</sup>, Dr. Paula Anel Cabrera Galeana<sup>1</sup>, Dr. Guillermina Ferro Flores<sup>3</sup>, Dr. Quetzali Gabriela Pitalúa Cortés<sup>1,2</sup>, Dr. Irma Soldevilla Gallardo<sup>1,4</sup>

<sup>1</sup>National Cancer Institute of Mexico, Tlalpan, Mexico, <sup>2</sup>Medica Sur, Tlalpan, Mexico, <sup>3</sup>National Institute of Nuclear Research, Toluca, Mexico, <sup>4</sup>ABC Medical Center, Álvaro Obregón, México

### **O82 Associated factors with positive [18F]FDG-PET/CT for distant metastasis in breast cancer**

**Dr. Ada Katherine Franco-Ardila**<sup>1</sup>, Iván Fabricio Vega-González<sup>1,2</sup>, Noiver Arbey Graciano-Vera<sup>3</sup>, Katherine Montoya-Lezcano<sup>4</sup>, Sonia Luz Gómez-Garcés<sup>1</sup>, Lina María López-Vélez<sup>2</sup>, Indira Díaz-Contreras<sup>1</sup>

<sup>1</sup>Universidad Autónoma de Bucaramanga - Unab, Bucaramanga, Colombia,

<sup>2</sup>Clínica Las Américas AUNA, Medellín, Colombia, <sup>3</sup>Instituto de cancerología Las Américas AUNA, Medellín, Colombia, <sup>4</sup>Fundación IDEAS AUNA, Medellín, Colombia

### **O83 Development and Evaluation of a Novel Dual-Targeted <sup>68</sup>Ga-FAPI-TTP PET Probe for Enhanced Tumor Imaging**

**Mrs. Yi-fei Pei**<sup>1</sup>, Mrs. Xiao-Yi Guo<sup>1</sup>, Prof. Hua Zhu<sup>1</sup>, Prof. Zhi Yang<sup>1</sup>

<sup>1</sup>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China, Beijing, China

### **O84 Real-life applicability of Fluorocholine PET/CT in primary hyperparathyroidism**

Dr. Iván Vega<sup>1</sup>, **Dr. Mónica Vidal**<sup>2</sup>, Dra. Stefania Cruz<sup>3</sup>, Dr. Antonio Rivera<sup>4</sup>, Dr. Alejandro Delgado<sup>2</sup>, Dra. Indira Diaz<sup>5</sup>, Dra. Clara Arango<sup>2</sup>, Dra. Carolina Prieto<sup>2</sup>, Dr. Carlos Builes<sup>2</sup>

<sup>1</sup>Clínica Las Américas-AUNA, Medellín, Colombia, <sup>2</sup>Hospital Pablo Tobón Uribe, Medellín, Colombia, <sup>3</sup>Universidad Pontificia Bolivariana, Medellín, Colombia,

<sup>4</sup>Universidad de Antioquia, Medellín, Colombia, <sup>5</sup>Unidad Gammanuclear, Armenia, Colombia

### **O85 Patient-specific factors in radioactive Iodine (I-131) clearance in Differentiated Thyroid Cancer (DTC) treatment**

Mr George Thiveos<sup>1</sup>, Mr Theofanis Petropoulos<sup>1</sup>, Mr John Papantoniou<sup>1</sup>, Mrs Agelliki Kokkini-Paschou<sup>1</sup>, Mrs Garyfallia Livitsanou<sup>1</sup>, Dr Evangelia Skoura<sup>1</sup>, Dr Ioannis Datseris<sup>1</sup>, **Dr. Ioannis Koutsikos**<sup>1</sup>

<sup>1</sup>Henry Dunant Hospital Center, Athens, Greece

### **O86 Bayesian survival modeling in multiple myeloma: prognostic PET/CT value with missing data imputation, preliminary results**

**Dr. Eliana Andrea González Artunduaga**, Estadístico PhD Nelson Cruz, MD

Hematólogo Kenny Galvez

<sup>1</sup>Medico Nuclear IDIME, Bogotá, Colombia

### **O87 From Variability to Equity: An Eight-Year Retrospective Analysis of I-131 Therapeutic Practices in a Nuclear Medicine Service**

**Lic. Mariano Portillo**<sup>1</sup>, Dr. Martina Musumeci<sup>1</sup>, Lic Marcos Mussio<sup>1</sup>, Tec Delfina Eugeni<sup>1</sup>, Dr Luciana Arburua<sup>1</sup>, Tec Ariel Arispe<sup>1</sup>, Dr. Silvina Racioppi<sup>1</sup>

<sup>1</sup>Servicio de Medicina Nuclear, Instituto Alexander Fleming, Buenos Aires, Argentina

**O88 Immunosuppressive molecular mechanisms potentially supporting development and progression of haematological malignancies triggered by abnormal or accidental exposure to nuclear irradiation**

Dr Inna Yasinska<sup>1</sup>, **Dr. Vadim Sumbayev**<sup>1</sup>

<sup>1</sup>University Of Kent, Chatham Maritime, United Kingdom

**O89 SPECT-CT in Primary Hyperparathyroidism: The Intermediate Localization Method**

**Dr. Carlos Collaud**<sup>1</sup>, Dra. Verónica Santana<sup>1</sup>, Dra. Sandra Sunagua<sup>1</sup>, Dra. Irene Arma<sup>1</sup>, Dra. Isabel Hume<sup>1</sup>, Dra Constanza Cianciarelli<sup>1</sup>, Dra. María Chacón<sup>1</sup>, Dra. Nadia Pabstleben<sup>1</sup>, Dra. Ana Mollerach<sup>1</sup>, Dra. Ana Mollerach

<sup>1</sup>Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

**O90 Multiparametric Radiomic Analysis Based on 18F-FDG PET, MRI and Biopsy for Predicting Pathological Complete Response to Breast Cancer Neoadjuvant Chemotherapy**

**Mr. Marco Guarín**<sup>1</sup>, Ms. Carolina Tinetti<sup>2</sup>, Mr. Mauro Namías<sup>2</sup>

<sup>1</sup>Instituto Nacional de Cancerología, Bogotá, Colombia, <sup>2</sup>Fundación Centro Diagnóstico Nuclear, Buenos Aires, Argentina

## **P001 Myocardial perfusion in patients with suspected coronary artery disease: association with troponin T levels in three centers in Bogotá**

**Dr. María Camila Bedoya González<sup>1</sup>**, Dr. Andrea Carolina Suárez Echavez<sup>1</sup>, Dr. Mauricio Andrés Hinojosa Vidal<sup>1</sup>, Dr. Alejandro Cortés Polanía<sup>1</sup>, Dr. Humberto Varela Ramírez<sup>1</sup>

<sup>1</sup>Fundación Universitaria de Ciencias de la Salud, Bogotá d.c., Colombia, <sup>2</sup>Fundación Universitaria Sanitas, Bogotá d.c., Colombia, <sup>3</sup>Clinicas Colsanitas, Bogotá d.c., Colombia

## **P002 Agreement of left ventricular ejection fraction by echocardiography and SPECT in patients with chest pain and suspected ischemia**

**Dr. Angie Cabrera Rojas<sup>1</sup>**, Dr. César García Quintanilla<sup>2</sup>, Dr. Javier Rodríguez Prada<sup>3</sup>, Dr. Adriana Reyes González<sup>4</sup>

<sup>1</sup>Universidad Autónoma de Bucaramanga, Floridablanca, Colombia, <sup>2</sup>SPECT Medicina Nuclear SAS, Floridablanca, Colombia, <sup>3</sup>Unidad de Investigación y Educación, Instituto del Corazón de Bucaramanga, Floridablanca, Colombia, <sup>4</sup>Universidad Autónoma de Bucaramanga, Floridablanca, Colombia

## **P003 Correlation between Chagas myocardiopathy and heart failure with sudden death over a 10-year period**

**Lic. Elizabeth Huanca<sup>1</sup>**, Doctor Raúl Araujo, licenciado Marcelo Torrez, Licenciada Patricia Bernal, Ingeniero Alfredo Zambrana, Doctora Greta Vargas, Doctor Daniel Salinas

<sup>1</sup>Universidad San Francisco Xavier De Chuquisaca, Sucre, Bolivia

## **P004 Experience at a university hospital with positron emission tomography using fluorine-18-labeled glucose metabolism in inflammatory/infectious cardiovascular processes**

**Dr. Teresa Massardo<sup>1</sup>**, Dr. Juan Dupouy<sup>1</sup>, Dr. Alejandro Rojas, Dr. José Tomás Donoso, Dr. Diego Palma, Dr. Daniel Saavedra, Dr. Francisco Javier Gómez<sup>1</sup>, Dr. Rocio Hidalgo<sup>1</sup>, Dr. Wilfredo Navarrete, Dr. Axel Aranguiz<sup>1</sup>, Dr. Daniel Schneider Dr Marcelo Llancaqueo<sup>1</sup>

<sup>1</sup>Hospital Clínico Universidad de Chile, Santiago/Chile, Chile, <sup>2</sup>hospital San Juan De Dios, Santiago/Chile, Chile

## **P005 18F-FDG PET/CT for the Detection and Reclassification of Infective Endocarditis in Corrected Congenital Heart Disease**

**Mrs. Sonia Simona Traverso**, MD Roxana Campisi, MD Jessica Herrero, MD Christian González, MD Calderón Laura, MD Paola Corona, MD Nicolás Bustos, MD Florencia Arbolaza, MD Gabriel Bruno

<sup>1</sup>Nuclear Diagnostic Center (FCDN), CABA, Argentina

### **P006 Is Cardiac Amyloidosis an Underdiagnosed Disease? Defining Frequency in Colombia**

**Dr. Mónica Vidal**<sup>1</sup>, Dr. Alejandro Delgado<sup>1</sup>, Dr. Juan Luis Londoño<sup>2</sup>, Dr. Nilson López<sup>1</sup>  
<sup>1</sup>Hospital Pablo Tobón Uribe, Medellín, Colombia, <sup>2</sup>Hospital San Vicente Fundación, Medellín, Colombia

### **P007 Diagnostic Value of Dual-Time-Point 18F-Fluorocholine PET/CT in Hyperparathyroidism: A Latin American Retrospective Cohort**

**Dr. Melissa Álvarez**<sup>1</sup>, Dr. Rosita Nohemy Dorado Castillo<sup>1</sup>, Dr. Diana Carolina Quijano Galvis<sup>1</sup>, Dr. Luz Maritza Pabon Castilla<sup>1</sup>, Jefe de enfermería John Jairo Torres Gallego<sup>1</sup>, Jefe de enfermería Beatriz Elena Guzmán Narváez<sup>1</sup>, Técnico Juliana María Venegas Sanchez<sup>1</sup>, Técnico Jessenia Jimenez Moreno<sup>1</sup>, Técnico Javier Andrés Garcés Giraldo<sup>1</sup>, Técnico Jenner Pulido Pasaje<sup>1</sup>  
<sup>1</sup>Fundación Valle Del Lili, Cali, Colombia

### **P008 Stimulated Pre-Ablative Thyroglobulin: Can It Be Used as a Parameter to Avoid Ablation?**

**Dr. Irene Arma**<sup>1</sup>, Ana María Mollerach<sup>1</sup>, Isabel Hume<sup>1</sup>, Constanza Cianciarelli<sup>1</sup>, María José Chacón<sup>1</sup>, Ana Wayngarten<sup>1</sup>, Fabiana Russo Picasso<sup>1</sup>, Nadia Pabstleben<sup>1</sup>, Florencia Zalarrayan<sup>1</sup>, Carlos Collaud<sup>1</sup>  
<sup>1</sup>Hospital Italiano de Buenos Aires, CABA, Argentina

### **P009 Primary Cultures and FISH analysis in Mesenchymal Cells from Osteomalacia-Inducing Tumors (TIO)**

Dra. Patricia Gargallo<sup>1</sup>, **Dr. María José Bastianello**<sup>1</sup>, Lic Diego Biscochea<sup>1</sup>, Dr Roxana Chirico<sup>1</sup>, Grupo Argentino de TIO Grupo Argentino de TIO<sup>2</sup>, Tech Brenda Konowalik<sup>1</sup>  
<sup>1</sup>CEMIC University Hospital, Buenos Aires, Argentina, <sup>2</sup>Grupo Argentino de TIO, CABA, Argentina

### **P010 Diagnostic utility of 11C-methionine PET/CT in primary hyperparathyroidism: national experience in Uruguay**

**Dr. Eduardo Lischinsky**<sup>1</sup>, Dr. Omar Alonso<sup>1,2</sup>, Ismael Cordero<sup>1,2</sup>, Eduardo Savio<sup>1,2</sup>, Javier Giglio<sup>2</sup>, Dr. Juan Pablo Gambini<sup>1,2</sup>  
<sup>1</sup>CMNIM, Hospital De Clínicas "Dr. Manuel Quintela" - Universidad De La República, Montevideo, Uruguay, <sup>2</sup>Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay

### **P011 Synergistic role of 99mTc-MIBI radioguided surgery and ICG fluorescence in primary and secondary hyperparathyroidism: experience in three cases**

**Dr. Bettina Martinucci**<sup>1</sup>, Carolina Furtado<sup>1,2</sup>, Mirel Cabrera<sup>2</sup>, Ximena Camacho<sup>2</sup>, Marcos Tassano<sup>2</sup>, Omar Alonso<sup>1</sup>, Pablo Duarte<sup>3</sup>, Alarico Rodriguez<sup>3</sup>, Pablo Cabral<sup>2</sup>, Juan Pablo Gambini<sup>2,3</sup>  
<sup>1</sup>UA Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, UdelaR, Montevideo, Uruguay, <sup>2</sup>Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay, <sup>3</sup>Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay

**P012 Beyond the neck: utilizing 18-f-choline pet/ct to uncover the source of primary hyperparathyroidism**

**Dr. Alejandra Gabriela Salgado**<sup>1</sup>, Dr Laura Felipe<sup>1</sup>, Dr Antonella Kovic<sup>1</sup>, Dr Maria del Carmen Alak<sup>1</sup>

<sup>1</sup>Imat, Buenos Aires, Argentina

**P013 Role of PET/CT in the follow-up of large vessel vasculitis-an experience in a single center**

**Dr. Irene Arma**<sup>1</sup>, Dr Isabel Hume<sup>1</sup>, Dr Ana Mollerach<sup>1</sup>, Dr Constanza Cianciarelli<sup>1</sup>, Dr Nadia Pabstleben<sup>1</sup>, Dr María José Chacón<sup>1</sup>, Dr Ana Wayngarten<sup>1</sup>, Dr Sandra Sunagua<sup>1</sup>, University Technologist Mayra Borges<sup>1</sup>, Dr Carlos Collaud<sup>1</sup>

<sup>1</sup>Hospital Italiano de Buenos Aires, Caba, Argentina

**P014 Diagnostic Value of 18F-FDG PET/CT in Large-Vessel Vasculitis: A Retrospective Study from a Moroccan Cohort**

**Dr. Yasmine Lasry**<sup>1</sup>, Dr. Mahdi Ahmed Hassan, Dr. Abir Bakraoui Samlali, Dr. Achraf Msoune, Dr. Ali Benlemlih, Dr. Halima Batani, Dr. Hafsa Bensimimou, Dr. Zakaria Ouassfrar, Pr. Amal Guensi

<sup>1</sup>Ibn Rochd University Hospital, Casablanca, Morocco

**P015 The value of FDG PET- CT imaging in the management of patients with bone sarcoma and soft tissue sarcoma**

**Dr. Rawnak Afrin**<sup>1</sup>, Dr. Shaila Sharmin<sup>1</sup>, Dr. Afroza Akhter<sup>1</sup>, Dr. Mohana Hossain<sup>1</sup>, Prof. Shankar Biswas<sup>1</sup>, Dr. Sadia Hossain<sup>1</sup>, Dr. Farhana Rahman<sup>1</sup>

<sup>1</sup>Bangladesh Atomic Energy Commission, Dhaka, Bangladesh

**P016 Role of Bone Scintigraphy in Evaluating Painful Knee Arthroplasty: Outcomes from a Single-Centre Cohort**

Dr. Jigisha Amin<sup>1</sup>, Mr Shreyas Satish<sup>2</sup>, Dr Adeel Syed<sup>1</sup>, Dr Arman Parsai<sup>1</sup>, Dr Nagesh Nagabhusan<sup>1</sup>, Dr Tahir Hussain<sup>1</sup>, Dr Ewa Nowosinska<sup>1</sup>, Dr Manuela Vadrucci<sup>1</sup>, Dr Idris Badreddine<sup>1</sup>, Dr Mohan Krishnamurthy<sup>1</sup>, **Dr. Hosahalli K Mohan**

<sup>1</sup>Department of Nuclear Medicine, Barts Health NHS Trust, London, United Kingdom,

<sup>2</sup>Department of Bioengineering, Imperial College London, London, United Kingdom

**P017 Role of Bone Scintigraphy in Evaluating Painful Hip Arthroplasty: Outcomes from a Single-Centre Cohort**

Mr Shreyas Satish<sup>1</sup>, Dr. Jigisha Amin<sup>2</sup>, Dr Adeel Syed<sup>2</sup>, Dr Arman Parsai<sup>2</sup>, Dr Nagesh Nagabhusan<sup>2</sup>, Dr Tahir Hussain<sup>2</sup>, Dr Ewa Nowosinska<sup>2</sup>, Dr Manuela Vadrucci<sup>2</sup>, Dr Idris Badreddine<sup>2</sup>, Dr Mohan Krishnamurthy<sup>2</sup>, **Dr. Hosahalli K Mohan**

<sup>1</sup>Department of Bioengineering, Imperial College London, London, United Kingdom,

<sup>2</sup>Department of Nuclear Medicine, Barts Health NHS Trust, London, United Kingdom

**P018 Comparative Imaging in Painful Joint Arthroplasty: Bone Scintigraphy versus X-ray imaging**

**Dr. Hosahalli K Mohan**, Mr Shreyas Satish<sup>1</sup>, Dr. Jigisha Amin<sup>2</sup>, Dr Adeel Syed<sup>2</sup>, Dr Arman Parsai<sup>2</sup>, Dr Nagesh Nagabhusan<sup>2</sup>, Dr Tahir Hussain<sup>2</sup>, Dr Ewa Nowosinska<sup>2</sup>, Dr Manuela Vadrucci<sup>2</sup>, Dr Idris Badreddine<sup>2</sup>, Dr Mohan Krishnamurthy<sup>2</sup>

<sup>1</sup>Department of Bioengineering, Imperial College London, London, United Kingdom,

<sup>2</sup>Department of Nuclear Medicine, Barts Health NHS Trust, London, United Kingdom

**P019 Value of dual fluorine-18-L-dopa and fluorine-18-fluorodeoxyglucose positron emission tomography in parkinsonism**

**Dr. Gerson Castillo**<sup>1</sup>, Miguel Olarte<sup>1</sup>, Ana Piana<sup>1</sup>, Juan Chávez<sup>1</sup>

<sup>1</sup>Unidad PET/CT, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico

**P020 PISCOM: Advanced Multimodal Functional Neuroimaging Integration of PET and SPECT for Presurgical Epileptogenic Zone Localization**

**Dr. Katherine Quintero**<sup>1</sup>, Arnau Farré-Melero<sup>1</sup>, Nerea Gutiérrez<sup>2</sup>, Sandra Rama<sup>3</sup>, Carles Siscar<sup>4</sup>, Erick García-Hernández<sup>1</sup>, Aida Niñerola<sup>1,2,5</sup>, Andrés Perissinotti<sup>1,5</sup>, Xavier Setoain<sup>1,2,5</sup>

<sup>1</sup>Hospital Clinic Barcelona, Barcelona, Spain, <sup>2</sup>Universitat de Barcelona, Barcelona, Spain, <sup>3</sup>Hospital Universitario de Salamanca, Salamanca, Spain, <sup>4</sup>Hospital Universitari Doctor Peset de Valencia, Valencia, Spain, <sup>5</sup>Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), ISCIII., Barcelona, Spain

**P021 Artificial intelligence as an assistant in the interpretation of 18F-FDG PET/CT in lymphomas according to the Deauville and Lugano criteria**

**Dr. Luis Colmener**<sup>1</sup>, Lic Juan Lubo<sup>2</sup>, Dr José Calderón<sup>2</sup>

<sup>1</sup>Gamanuclear, Cali, Colombia, <sup>2</sup>Medicina Nuclear SA, Valledupar, Colombia

**P022 Experience of the National Cancer Institute of Colombia with Lutetium-177 PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer**

**Dr. Viviana Andrea Daza Betancourt**<sup>1</sup>, Dr. Daniel Felipe Galindo Cortés<sup>1</sup>, Dr. Hernando Andrés Benavides Jiménez<sup>1</sup>, Dr. Camila Andrea Potal de Motta<sup>1</sup>, Dr. Alejandro Jiménez Baraya<sup>1</sup>, Dr. María Alejandra Gómez Marting<sup>1</sup>, Dr. Marylin Acuña Hernández<sup>2</sup>, Dr. Adriana Quiteria Buitrago Gómez<sup>2</sup>

<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, Colombia, <sup>2</sup>Instituto Nacional de Cáncer, Bogotá, Colombia

**P023 Standardization of tumor burden in lymphomas with PET/CT: integration of volumetric metrics Deauville and Lugano criteria to optimize clinical decision-making**

**Señor. Juan Lubo Marin**<sup>1</sup>, Dr. Luis Colmener<sup>2,4,6</sup>, Dr. José Calderón<sup>1</sup>, Dr Sinay Arevalo<sup>3,5</sup>

<sup>1</sup>Medicina Nuclear S. A., Valledupar, Colombia, <sup>2</sup>Gamanuclear, Valle del Cauca, Colombia, <sup>3</sup>Medicina Nuclear Los Nogales, Bogotá, Colombia, <sup>4</sup>PETCIMAGENES, Quito, Ecuador, <sup>5</sup>Universidad del Rosario, Bogotá, Colombia, <sup>6</sup>Grupo Conceptualizando, Cali, Colombia

**P024 Clinical experience in oncologic PET/CT: radiomics-based quantification to complement clinical interpretation and standardize tumor burden assessment**

**Señor. Juan Lubo Marin**<sup>1</sup>, Dr. Luis Colmener<sup>2</sup>, Dr. José Calderón<sup>1</sup>

<sup>1</sup>Medicina Nuclear S. A., Valledupar, Colombia, <sup>2</sup>Gamanuclear, Cali, Colombia

**P025 Implementation of PET/CT 2.0 Reports: From Descriptive to Quantitative in Personalized Oncologic Practice**

**Señor. Juan Lubo Marín**<sup>1</sup>, Dr. Luis Colmener<sup>2</sup>, Dr. José Calderón<sup>1</sup>

<sup>1</sup>Medicina Nuclear S. A., Valledupar, Colombia, <sup>2</sup>Gamanuclear, Cali, Colombia

**P026 Metabolic activity in primary tumor and metastatic lesions of breast cancer according to molecular subtype: preliminary analysis with pet/ct**

**Dr. Sofía Velázquez<sup>1</sup>**, Dra. Yazmín Sánchez<sup>1</sup>, Dr. Miguel Olarte<sup>1</sup>

<sup>1</sup>Facultad de Medicina Unam, Coyoacan, Mexico

**P027 18F-PSMA PET/CT in Prostate Cancer: Initial Experience and Theranostic Roadmap from Bangladesh**

**Dr. Afroza Akhter<sup>1</sup>**, Dr. Shaila Sharmin<sup>1</sup>, Dr. Rawnak Afrin<sup>1</sup>, Dr. Farhana Rahman<sup>1</sup>, Dr. Sadia Hossain<sup>1</sup>, Prof. Shankar Biswas<sup>1</sup>

<sup>1</sup>Institute of Nuclear Medicine and Allied Sciences, INMAS Dhaka, Bangladesh Atomic Energy Commission, Dhaka, Bangladesh

**P028 99mTc-Labeled LHRH Analog versus Trastuzumab: Comparative Targeted Preclinical Imaging of Human Breast Cancer Models via LHRH/HER2 Receptors**

**Dr. Lucía Alfaya<sup>1</sup>**, Dr Ximena Camacho<sup>1</sup>, Dr Mirel Cabrera<sup>1</sup>, Dr María Fernanda García<sup>1</sup>, Msc Ana Laura Reyes<sup>2</sup>, TRI Andrea Paolino<sup>2</sup>, Dr Eduardo Savio<sup>2</sup>, Dr Juan Pablo Gambini<sup>2,3</sup>, Dr Pablo Cabral<sup>1</sup>

<sup>1</sup>Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay, <sup>2</sup>Centro Uruguayo de Imagenología Molecular, CUDIM, Montevideo, Uruguay, <sup>3</sup>Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

**P029 Staging positron emission tomography in multiple myeloma: extramedullary disease as a predictor of adverse outcomes, cohort 2014–2023**

**Dr. Melissa Álvarez<sup>1</sup>**, Dr. Rosita Nohemy Dorado Castillo<sup>1</sup>, Dr. Joaquín Donald Rosales<sup>1</sup>, Dr. Ana María Aguilar González<sup>2</sup>, Dr. Juliana Hernández Bolívar<sup>1</sup>, Dr. Juan David Marín Escobar<sup>1</sup>, Dr. Kevin Bueno Espitia<sup>1</sup>, Dr. Diana Carolina Quijano Galvis<sup>1</sup>, Dr. Luz Maritza Pabón Castilla<sup>1</sup>, Dr. Lina María Góez Mogollón<sup>1</sup>

<sup>1</sup>Fundación Valle Del Lili, Cali, Colombia, <sup>2</sup>Hospital Universitario del Valle, Cali, Colombia

**P030 Treatment with 177Lu-PSMA radioligand: tumor volume and PSA behavior and their relationship with overall survival**

Dr. Matias Cimin<sup>1</sup>, Dra. Roxana Chirico<sup>1</sup>, Dra, Nathalie Abreu<sup>1</sup>, Lic German Pitarch<sup>1</sup>, Lic Brenda Konowalik<sup>1</sup>, Dr. Alejandro Valda<sup>1</sup>, **Dr. Maria Jose Bastianello<sup>1</sup>**

<sup>1</sup>CEMIC University Hospital, Buenos Aires, Argentina

**P031 Correlation between PSA levels, SUVmax and total tumor volume (TTV) in evaluation response therapy using 18F-PSMA-PET/CT in prostate cancer (PC)**

**Dr. Indira Eliana Díaz Contreras<sup>1</sup>**, Dr. Ada Franco Ardila<sup>2</sup>, Dr. Iván Vega González<sup>3</sup>

<sup>1</sup>Gamanuclear LTDA, Armenia, Colombia, <sup>2</sup>Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia, <sup>3</sup>Clínica Las Américas AUNA, Medellín, Colombia

**P032 Long axial field of view (LAFOV) PET-CT scanners in oncology**

**Prof. Antonia Dimitrakopoulou-Strauss<sup>1</sup>**, Dr Leyun Pan<sup>1</sup>, Prof. Christos Sachpekidis<sup>1</sup>

<sup>1</sup>German Cancer Research Center, Heidelberg, Germany

**P033 Bronchopulmonary neuroendocrine tumors: characterization with [18F]OC and [18F]FDG PET/CT**

**Dr. Abril Ariadna Flores Pérez<sup>1</sup>**, Dr. Claudia Contreras-Rivera<sup>1</sup>, Dr. Ana Lucía Calderón-Ávila<sup>1</sup>, Dr. Miguel Ángel Olarte-Casas<sup>1</sup>  
<sup>1</sup>Pet/ct Unam, Mexico City, Mexico

**P034 Sacral insufficiency fracture after radioterapy treatment for cervical cancer: detection and characterization by 18F-FDG-PET/CT: 12 years of experience**

**Dr. Maximiliano Francabandiera<sup>1</sup>**, Dra. Paola Corona<sup>1</sup>, Dra. Florencia Arabolaza<sup>1</sup>, Dr. Federico Matorra<sup>1</sup>, Dr. Nicolás Bustos<sup>1</sup>, Dra. Berenice Fiamingo<sup>1</sup>, Dr. Christian González<sup>1</sup>, Dra. Sonia Traverso<sup>1</sup>, Dr. Gabriel Bruno<sup>1</sup>  
<sup>1</sup>Centro Diagnostico Nuclear, Caba, Argentina

**P035 Unspecific mesenteric uptake on 18F-PET/CT in post-treatment lymphoma: a “don’t touch” pitfall**

**Dr. Maximiliano Francabandiera<sup>1</sup>**, Dra. Paola Corona<sup>1</sup>, Dr. Christian González<sup>1</sup>, Dra. Florencia Arabolaza<sup>1</sup>, Dr. Nicolás Bustos<sup>1</sup>, Dra. Berenice Fiamingo<sup>1</sup>, Dra. Sonia Traverso<sup>1</sup>, Dr. Gabriel Bruno<sup>1</sup>  
<sup>1</sup>Fundación Centro Diagnostico Nuclear, Caba, Argentina

**P036 Clinical Significance of Sentinel Lymph Node Scintigraphy in Breast Cancer Patients Attended by the Brazilian Public Health Service**

**Mrs. Stephanie Freitas<sup>1</sup>**, Ms. Ana Julya Fernandes<sup>2</sup>, Dr. Sandra Sanches<sup>1,2</sup>, Dr. Talita Santos<sup>2</sup>, Dr. Priscila Santana<sup>2</sup>, Dr Luciene Mota<sup>2</sup>  
<sup>1</sup>Hospital das Clinicas da Universidade Federal De Minas Gerais, Belo Horizonte, Brazil, <sup>2</sup>Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

**P037 Disease-Free Survival in Thyroid Cancer Patients with Extrathyroidal Extension as the Sole Risk Factor**

Dr. Helen Johana Mejía Efeer<sup>1</sup>, **Dr. María Alejandra Gómez Marting<sup>1</sup>**, Dr. Adriana Quiteria Buitrago Gómez<sup>2</sup>, Dr. Edward Díaz Rodríguez<sup>2</sup>, Dr. Diana Cuéllar<sup>2</sup>, Dr. Humberto Varela Ramírez<sup>1</sup>, Dr. Viviana Andrea Daza Betancourt<sup>1</sup>, Dr. Angie Paola Llanos Cuellar<sup>1</sup>, Dr. Ana Milena Guadrón Naranjo<sup>1</sup>, Dr. Hernando Andrés Benavides Jiménez<sup>1</sup>  
<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, D.C., Colombia, <sup>2</sup>Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

**P038 Local experience with post-surgical hepatic remnant assessment using hepatobiliary SPECT scintigraphy**

Dr. Alejandro Rojas<sup>1</sup>, **Dr. Francisco Gomez<sup>1</sup>**, Dr. Carlos Mandiola<sup>1</sup>, Dr. Jaime Castillo<sup>1</sup>, Dr. Juan Dupouy<sup>1</sup>, Dr. José Tomás Donoso<sup>1</sup>, Dr. Rocío Hidalgo<sup>1</sup>, Dr. Byron Riedel<sup>1</sup>, Dr. Francisco Tortorolo<sup>1</sup>, Ms. Catalina Serrano<sup>1</sup>, Dr. Teresa Massardo<sup>1</sup>  
<sup>1</sup>Hospital Clínico Universidad de Chile, Santiago, Chile

### **P039 Intraoperative ICG Fluorescence for Perfusion Assessment in Digestive Tract Surgery**

**Dr. Bettina Martinucci**<sup>1</sup>, Carolina Furtado<sup>1,2</sup>, Mirel Cabrera<sup>2</sup>, Ximena Camacho<sup>2</sup>, Marcos Tassano<sup>2</sup>, Omar Alonso<sup>1</sup>, Gustavo Burroso<sup>3</sup>, Pablo Duarte<sup>3</sup>, Pablo Cabral<sup>2</sup>, Juan Pablo Gambini<sup>2,3</sup>

<sup>1</sup>UA Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas Dr. Manuel Quintela, Facultad de Medicina, UdelaR, Montevideo, Uruguay, <sup>2</sup>Centeo de Investigaciones Nucleares, UdelaR, Montevideo, Uruguay, <sup>3</sup>Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay

### **P040 Utility of 18F-FDG PET/CT in the characterization of solitary pulmonary nodule**

**Dr. Rosita Aracely Mendoza Santa Cruz**<sup>1</sup>, Dr. Daniel Santos Orihuela<sup>1</sup>, Dr. Benjamín Gamarra Mújica<sup>1</sup>

<sup>1</sup>Guillermo Almenara Irigoyen National Hospital, LIMA, Perú

### **P041 Preliminary analysis of clinical and radiomic correlations in castration-resistant prostate cancer using consecutive [18F]PSMA-PET**

**Dr. Claudia Paola Pedraza García**<sup>1</sup>, Dr Miguel Ángel Olarte Casas<sup>1</sup>, Dra Ana Karina Miranda Playas<sup>1</sup>, Dra Oliva Granados Rangel<sup>1</sup>, Dr Gustavo Rafael Govea Torres<sup>2</sup>, Dr Arturo Avendaño Estrada<sup>3,4</sup>

<sup>1</sup>Unidad PET/CT, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad De México, México, <sup>2</sup>Departamento de Fisiología, Universidad Autónoma de Nuevo León, Monterrey, México, <sup>3</sup>Unidad Radiofarmacia-Ciclotrón, División de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad De México, México, <sup>4</sup>Centro de Investigación sobre el Envejecimiento, Centro de Investigación y de Estudios Avanzados Sede Sur, México, Ciudad de México, México

### **P042 Prognostic value of baseline 18F-FDG PET/CT metabolic parameters in breast cancer and their association with histologic features and disease-free survival**

**Dr. Bethsabel Rodriguez Encinas**<sup>1</sup>, MD Eva Lorena Valadez Montero<sup>1</sup>, MD Irma Soldevilla Gallardo<sup>1</sup>

<sup>1</sup>The American British Cowdray Medical Center, Mexico City, Mexico

### **P043 Diagnostic Value of Quantitative Parameters of Intraprostatic Uptake of F18-PSMA-1007 in the Risk Classification of Prostate Cancer**

**Prof. Juan Carlos Rojas Montenegro**<sup>1</sup>, Dr. Sebastián Ayala Zapata<sup>2</sup>, Prof. Miguel Angel Olarte Casas<sup>3</sup>

<sup>1</sup>Universidad Del Valle - Facultad de Salud - Medicina Nuclear, Cali, Colombia, <sup>2</sup>Hospital Universitario del Valle - Facultad de Salud - Medicina Interna, Cali, Colombia, <sup>3</sup>Universidad Autonoma de Mexico - Facultad de Medicina - Unidad de PET/CT, Ciudad de Mexico, Mexico

#### **P044 Clinical impact of somatostatin analogue PET/CT on therapeutic decision-making in neuroendocrine tumors**

**Dr. Florencia Savio**<sup>1</sup>, Dr. Ivan Lyra, Dra Dahiana Amarillo, Dr. Diego Ferreira, Dra. Florencia Gentini, Dr Mathías Jeldrés, Dra. Cecilia Castillo, Dr. Gabriel Krygier, Ing. Rafael Alonso, Dra Marisa Fazzino, Dr Eduardo Savio, Dr Alarico Rodríguez, Dr Gustavo Burroso, Dr Nicolás Niell, Dr Juan Pablo Gambini

<sup>1</sup>Unidad Académica de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas "Dr. Manuel Quintela", Facultad de Medicina Udelar, Montevideo, Uruguay,

<sup>2</sup>Unidad Académica de Oncología Clínica, Hospital de Clínicas "Dr. Manuel Quintela", Facultad de Medicina Udelar, Montevideo, Uruguay, <sup>3</sup>Servicio de Oncología Clínica, Asistencial Médica Maldonado, Maldonado, Uruguay, <sup>4</sup>Servicio de Oncología Clínica, Médica Uruguaya, Montevideo, Uruguay, <sup>5</sup>Servicio de Oncología Clínica, Hospital Británico, Montevideo, Uruguay, <sup>6</sup>Unidad Académica de Métodos Cuantitativos, Facultad de Medicina Udelar, Montevideo, Uruguay, <sup>7</sup>Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay

#### **P045 Clinical impact of 99mTc-hynic-toc spect/ct in neuroendocrine tumors: experience from an oncology hospital in Ecuador**

**Dr. Christian Toalongo Moreno**<sup>1,2</sup>, Dra. Karina Zurita Vivero<sup>2</sup>, Dr. Paul Villalba Meneses<sup>2</sup>

<sup>1</sup>SOLCA Oncology Hospital, Guayaquil, Ecuador, <sup>2</sup>Indoamérica Technological University, Quito, Ecuador

#### **P046 Male Breast Cancer and F-18 FDG PET/CT, Preliminary Results**

**Prof. Funda Üstün**<sup>1</sup>, Mrs Büşra Özdemir Günay<sup>2</sup>, Mr Aygün Aslan<sup>3</sup>

<sup>1</sup>Trakya University Medical Faculty, Edirne, Turkey, <sup>2</sup>Giresun Training and Research Hospital, Giresun, Turkey, <sup>3</sup>Rize Training and Research Hospital, Rize, Turkey

#### **P047 Combined predictive value of quantitative PET/CT and multiparametric MRI parameters for risk stratification in prostate cancer: a preliminary analysis**

**MD Eva Lorena Valadez Montero**<sup>1</sup>, MD Bethsabel Rodriguez Encinas<sup>1</sup>

<sup>1</sup>Centro Medico ABC, Mexico City, Mexico

#### **P048 Role of Meckel's Scan for Gastrointestinal Bleeding and/or Anemia: Experience in Nuclear Medicine, Hospital San Juan de Dios, Chile**

**Dr. Sebastián León**<sup>1</sup>, Dra. Gilda Donoso<sup>1,2</sup>, Dra. Gabriela Mundaca<sup>2</sup>

<sup>1</sup>Universidad de Chile, Santiago, Chile, <sup>2</sup>Hospital San Juan de Dios, Santiago, Chile

#### **P049 Reproducibility of Volumetric Parameters in [<sup>18</sup>F]-PSMA-1007 PET/CT: A Comparison Between Two Analysis Platforms**

**Mrs. Nathaly Barbosa**<sup>1</sup>, Dr Daniel Felipe Galindo Cortés<sup>2</sup>, MSc Adriana Carolina Aya-Porto<sup>1</sup>, Dr Clarena Zuluaga<sup>1</sup>, Dr Carlos Granados<sup>1</sup>

<sup>1</sup>Centro de Tratamiento e Investigación Sobre Cáncer, Bogota, Colombia,

<sup>2</sup>Fundación Universitaria Sanitas, Bogota, Colombia

#### **P050 Baseline [<sup>18</sup>F]PSMA-1007 PET Uptake Predicts Lesion Absorbed Dose During <sup>177</sup>Lu-PSMA-I&T Therapy**

**Mrs. Nathaly Barbosa**<sup>1</sup>, Dr Clarena Zuluaga<sup>1</sup>, Dr Carlos Granados<sup>1</sup>

<sup>1</sup>Centro de Tratamiento e Investigación Sobre Cáncer, Bogota, Colombia

### **P051 Protocol optimization for myocardial perfusion studies, based on image quality parameters**

**Señora. Juana Cárdenas Rojas**<sup>1</sup>, Señora. Andrea Abril Fajardo<sup>1</sup>, Señor. Agustín Daza Moreno<sup>2</sup>, Señora. Sara Rámirez Aguirre<sup>2</sup>, Señora. Claudia Gutiérrez Villamil<sup>3</sup>  
<sup>1</sup>Universidad Nacional de Colombia, Bogotá, Colombia, <sup>2</sup>Fundación Santa Fe, Bogotá, Colombia, <sup>3</sup>Fundación Cardioinfantil, Bogotá, Colombia

### **P052 Real-Time Computational Framework for Standardizing Bed Speed Acquisition in PET/CT Imaging Using NECR-Based Predictive Metrics**

**Lic. Yesenia Saldierna Martínez**<sup>1</sup>, Dra. Rocío Hernández Álvarez<sup>1</sup>, MSc Cristhoper Camacho Herrera<sup>1,2</sup>  
<sup>1</sup>Hospital Ángeles Centro Sur, Queretaro, Mexico, <sup>2</sup>Nuclear Medicine World, Ciudad de Mexico, Mexico

### **P053 Analysis of the diversity and volume of PET CT procedures in prostate cancer patients performed at CUDIM Montevideo-Uruguay: statistical survey**

**Dr. Gerardo Dos Santos**<sup>1,2</sup>, Dra. Agustina Bancho<sup>1</sup>, Dr. César Ferreira<sup>2</sup>, Dr. Eduardo Lischinsky<sup>2</sup>, Technologist Ismael Cordero<sup>1</sup>, Dr. Omar Alonso<sup>1,2</sup>  
<sup>1</sup>Uruguayan Center of Molecular Imaging (CUDIM), Montevideo, Uruguay, <sup>2</sup>Nuclear Medicine and Molecular Imaging Center, Clinical Hospital "Dr. Manuel Quintela", University of Uruguay, Montevideo, Uruguay

### **P054 Redefining the Nursing Role in Nuclear Medicine: Furosemide-Assisted Preparation to Optimize Pelvic Imaging in Genitourinary Cancer**

**Lic. Yesenia Saldierna Martínez**<sup>1</sup>, Dra Rocío Hernández Álvarez<sup>1</sup>, MSc Cristhoper Camacho Herrera<sup>1,2</sup>  
<sup>1</sup>Hospital Ángeles Centro Sur, Queretaro, Mexico, <sup>2</sup>Nuclear Medicine World, Ciudad de Mexico, Mexico

### **P055 Retreatment with 177Lu-DOTATATE in Patients with Neuroendocrine Tumors: Experience at an Oncology Center**

**Dr. Hernando Andrés Benavides Jiménez**<sup>1</sup>, Dr Edward Andres Diaz Rodriguez<sup>2</sup>, Dra Viviana Andrea Daza Betancourt<sup>1</sup>  
<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, Colombia, <sup>2</sup>Instituto Nacional de Cancerología , Bogota, Colombia

### **P056 Transarterial radioembolization with Y-90 and Ho-166 in patients with portal vein thrombosis**

**Dr. Sandor Czibor**<sup>1,2</sup>, Boglarka Toth<sup>3,4</sup>, Dr. Domonkos Nadasdy-Horvath<sup>1</sup>, Dr. David Korda<sup>4</sup>, Gabriella Taba<sup>5</sup>, Dr. Andras Bibok<sup>4</sup>, Dr. Denes Horvathy<sup>4</sup>  
<sup>1</sup>Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, Hungary, <sup>2</sup>Pozitron Medical Diagnostics Ltd., Budapest, Hungary, <sup>3</sup>Faculty of Medicine, Semmelweis University, Budapest, Hungary, <sup>4</sup>Department of Interventional Radiology, Semmelweis University, Budapest, Hungary, <sup>5</sup>Radiation Protection Service, Semmelweis University, Budapest, Hungary

**P057 Correlation between PSA kinetic parameters and progression-free and overall survival in a cohort of patients treated with 177LuPSMA in Colombia**

**Dr. Daniel Felipe Galindo-Cortés<sup>1</sup>**, Dr. Viviana Andrea Daza-Betancourt<sup>1</sup>, Dr. Sofía Albornoz-Gutiérrez<sup>1</sup>, Dr Valeria Andrea Villanueva Bueno<sup>1</sup>, Dr Marilyn Acuña-Hernández<sup>2</sup>, Dr Adriana Quiteria Buitrago-Gómez<sup>2</sup>

<sup>1</sup>Fundación Universitaria Sanitas, Bogotá, Colombia, <sup>2</sup>Instituto Nacional de Cancerología, Bogotá, Colombia

**P058 Discordant biochemical and radiological responses to Lu177-PSMA therapy in real-world mCRPC patients**

**Dr. Óscar Herrera Fomperosa<sup>1</sup>**, Dra. Irma Soldevilla Gallardo<sup>1</sup>

<sup>1</sup>Centro Medico Abc, Álvaro Obregon, Mexico

**P059 Impact of pharmacogenomics on the management of patients with metastatic castrate-resistant prostate cancer requiring radionuclide therapy**

**Dr. Nihaad Jacobs<sup>1</sup>**, Ms Nosipho Mabizela<sup>1</sup>, Dr Raisa Wessels<sup>1,2</sup>, Prof Collet Dandara<sup>1</sup>, Dr Khanyisile Hlongwa<sup>1</sup>, Dr Stuart More<sup>1</sup>

<sup>1</sup>University of Cape Town, Cape Town, South Africa, <sup>2</sup>National Health Laboratory Service, Cape Town, South Africa

**P060 Implementation of comprehensive geriatric assessment in older adults with differentiated thyroid cancer who require in-hospital radioiodine therapy**

**Dr. M. Josefina Jofre Manieu<sup>1</sup>**, Dr. Rocío Quilodrán<sup>1</sup>

<sup>1</sup>Fundación Arturo López Pérez, Santiago, Chile

**P061 Predictive factors of progression in neuroendocrine tumors and paragangliomas treated with lutetium-177-DOTATATE therapy**

**Dr. Óscar Lucio<sup>1</sup>**, Dr. Miguel Corza<sup>1</sup>

<sup>1</sup>Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico

**P062 The role of SPECT/CT imaging after radionuclide therapy in metastatic castration-resistant prostate cancer**

**Mrs. Lisa MacFarlane<sup>1,2</sup>**

<sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, Australia, <sup>2</sup>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

**P063 Exponential growth of lutetium-177 therapies at a leading cancer center in Latin America**

**Lic. Mariano Portillo<sup>1</sup>**, Dr. Martina Musumeci<sup>1</sup>, Lic. Marcos Mussio<sup>1</sup>, Tec. Luis Genovese<sup>1</sup>, Tec. Delfina Eugeni<sup>1</sup>, Tec. Ariel Arispe<sup>1</sup>, Dr. Luciana Arburua<sup>1</sup>, Dr. Silvina Racioppi<sup>1</sup>

<sup>1</sup>Servicio de Medicina Nuclear, Instituto Alexander Fleming, Buenos Aires, Argentina

**P064 Low Risk, Lasting Vigilance: Recurrence Patterns in Papillary Thyroid Microcarcinoma**

**Dr. Shaila Sharmin<sup>1</sup>**, Dr. Afroza Akhter<sup>1</sup>, Dr. Mohana Hossain<sup>1</sup>, Dr. Rahima Perveen<sup>1</sup>, Dr. Rawnak Afrin<sup>1</sup>, Dr. Tanima Biswas<sup>1</sup>, Dr. Sadia Hossain<sup>1</sup>, Dr. Sabrina Islam<sup>1</sup>, Dr. Farhana Rahman<sup>1</sup>, Dr. Tanvirul Hasan<sup>1</sup>, Dr. Shankar Biswas<sup>1</sup>

<sup>1</sup>Institute Of Nuclear Medicine & Allied Sciences, INMAS, Dhaka, Bangladesh, Atomic energy commission, Dhaka, Bangladesh

**P065 Cost-utility analysis of [177Lu]PSMA therapy compared to Cabazitaxel in patients with mCRPC from the perspective of the Colombian Health System**

**Dr. Marylin Acuña Hernández<sup>1</sup>**, Dr Sebastián Camilo Venegas Osorio<sup>2</sup>, Magister Aurelio Mejía Mejía<sup>2</sup>

<sup>1</sup>Instituto Nacional de Cancerología - Universidad De Antioquia, Bogota, Colombia,

<sup>2</sup>Universidad de Antioquia, Medellin, Colombia

**P066 Cost-utility of therapy with 177Lu-DOTAPEPTIDE: Systematic review of the literature**

**Dr. Marylin Acuña Hernández<sup>1</sup>**, Dr. Paula Alejandra Mendez Mercado<sup>2</sup>, Dr. Olga Liset Sánchez Orduz<sup>3</sup>

<sup>1</sup>Instituto Nacional de Cancerología - Universidad de Antioquia, Bogota, Colombia,

<sup>2</sup>Los Cobos Medical Center, Bogota, Colombia, <sup>3</sup>SPECT Medicina Nuclear SAS, Bucaramanga, Colombia

**P067 Cost-utility of therapy with 177Lu-PSMA: Systematic review of the literature**

**Dr. Marylin Acuña Hernández<sup>1</sup>**, Dr. Paula Alejandra Méndez Mercado<sup>2</sup>, Dr. Olga Liset Sánchez Orduz<sup>3</sup>

<sup>1</sup>Instituto Nacional de Cancerología - Universidad de Antioquia, Bogota, Colombia,

<sup>2</sup>Los Cobos Medical Center, Bogota, Colombia, <sup>3</sup>SPECT Medicina Nuclear SAS, Bucaramanga, Colombia

**P068 Current situation and challenges of nuclear medicine In Perú**

**Dr. Shirley Alarcón<sup>1</sup>**

<sup>1</sup>Clínica Ricardo Palma, Lima, Perú

**P069 Public/public-private synergy in the creation of the Nuclear Medicine Service in Uruguay**

**Lic. Andreína Blanco<sup>2</sup>**, Dr. Alarico Rodríguez<sup>1</sup>, Dr. Gustavo Burroso<sup>1</sup>, Dr. Pablo Duarte<sup>1</sup>, Dr. Carlos Heugerot<sup>2</sup>, Dr. Pablo Cabral<sup>2</sup>, Prof. Juan Gambini<sup>1</sup>

<sup>1</sup>Cudim, Montevideo, Uruguay, <sup>2</sup>DNSFFAA, Uruguay

**P070 The current state of the PET Imaging Site Qualification Program for amyloid PET scans conducted in Japan**

**Dr. Hirofumi Fujii<sup>1,2</sup>**, Dr. Yasuhiko Ikari<sup>3</sup>, Dr. Keisuke Tsuda<sup>4</sup>, Mr. Kazuaki Mori<sup>5</sup>, Dr. Ukihide Tateishi<sup>6</sup>, Dr. Kenji Hirata<sup>7</sup>, Dr. Hiromitsu Daisaki<sup>8</sup>, Dr. Makoto Hosono<sup>9</sup>, Dr. Hiroshi Ito<sup>10</sup>, Dr. Michio Senda<sup>3</sup>

<sup>1</sup>Japan Radioisotope Association, Tokyo, Japan, <sup>2</sup>National Cancer Center, Kashiwa, Japan, <sup>3</sup>Kobe City Medical Center General Hospital, Kobe, Japan, <sup>4</sup>Juntendo University, Tokyo, Japan, <sup>5</sup>Toranomon Hospital, Tokyo, Japan, <sup>6</sup>Institute of Science Tokyo, Tokyo, Japan, <sup>7</sup>Hokkaido University, Sapporo, Japan, <sup>8</sup>Gunma Prefectural College of Health Sciences, Maebashi, Japan, <sup>9</sup>Kindai University, Osakasayama, Japan, <sup>10</sup>Fukushima Medical University, Fukushima, Japan

### **P071 Implementation of the IAEA QUANUM Program to Achieve GMP Certification at CUDIM Radiopharmacy**

**Dr. Javier Giglio**<sup>1</sup>, Dra. Ingrid Kreimerman<sup>1</sup>, Chemistry Maia Zeni<sup>1</sup>, Dra. Ana Rey<sup>2</sup>, Dr. Alarico Rodríguez<sup>1</sup>, Dr. Gustavo Burroso<sup>1</sup>, Dr. Eduardo Savio<sup>1</sup>

<sup>1</sup>Departamento de Radiofarmacia, Centro Uruguayo de Imagenología Molecular (Cudim), Montevideo, Uruguay, <sup>2</sup>Área de Radioquímica, Facultad de Química, UdelaR, Montevideo, Uruguay

### **P072 Ejection fraction obtained manually during the rotary internship at the Institute of Nuclear Medicine of the San Francisco Xavier University**

**Lic. Elizabeth Huanca**<sup>1</sup>, Lic. Marcelo Torrez, Doctora Lidya Quevedo, Lic. Mery Orosco, Lic. Katherine Romero

<sup>1</sup>Universidad San Francisco Xavier De Chuquisaca, Sucre, Bolivia

### **P073 Research work practice program of radiopharmacy with an integrative approach to the 5th level of the career pharmacy at USFX**

**Lic. Elizabeth Huanca**<sup>1</sup>, Licenciada Rita Vasquez

<sup>1</sup>Universidad San Francisco Xavier De Chuquisaca, Sucre, Bolivia

### **P074 Project Management Applied to the Implementation of a Nuclear Medicine Service in Bogotá, Colombia: Experience and Proposal for Standardization**

**Dr. María Martínez**<sup>1</sup>, Ingeniería Lenys Roncancio, Física medica Lorena Sandoval

<sup>1</sup>Clinica Del Country, Bogota, Colombia

### **P075 Radiological Safety: Estimating Radiation Exposure for Non-Occupationally Exposed Healthcare Personnel in Nuclear Medicine Procedures**

**Mrs. Lorena Sandoval Castillo**<sup>1</sup>, Mrs. Sandra Barrera<sup>1</sup>, Mrs. Nidya Zambrano<sup>1</sup>, Mr. Carlos Quiroga<sup>1</sup>, Mr. Gerardo Cortés<sup>1</sup>

<sup>1</sup>Clínica Del Country, Bogotá, Colombia

### **P076 Reducing Extremity Radiation Exposure in Dynamic PET/CT Studies in Clinica del Country**

**Mrs. Lorena Sandoval Castillo**<sup>1</sup>, Mrs. Viviana Andrade<sup>1</sup>, Mrs. Claudia Piñeros<sup>1</sup>, Mr. Carlos Quiroga<sup>1</sup>, Mr. Gerardo Cortés<sup>1</sup>

<sup>1</sup>Clínica Del Country, Bogotá, Colombia

### **P077 Role of PET/MRI in localizing the epileptogenic focus in drug-resistant epilepsy**

**Dr. Génesis Rodríguez Ugalde**<sup>1</sup>, Dra. Lady Sánchez Gómez, Dr. Andrés Bello Murguía, Dr. José Antonio Serna Macías, Dr. Jorge Schalch De León.

<sup>1</sup>Hospital Privado, Ciudad de México, México



Organized by

In cooperation with



WORLD FEDERATION  
OF NUCLEAR MEDICINE  
AND BIOLOGY



ACMNIM  
ASOCIACIÓN COLOMBIANA  
DE MEDICINA NUCLEAR  
E IMÁGENES MOLECULARES



alasbimn  
Asociación Latinoamericana de Sociedades  
de Biología y Medicina Nuclear



IAEA

Organizing Agency

**Bco Congressos**  
Barceló  
GRUPO

Pl. Europa, 17-19 1ª planta  
08908 L'Hospitalet de Llobregat, Barcelona (España)  
+34 93 882 38 78 · wfnmb2026@bcocongresos.com